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Supplementary Note 1 
Study Descriptions 
This study includes data from the CHARGE and UCLEB Consortia. For all studies, each participant provided written 
informed consent. The Institutional Review Board at the parent institution for each respective study approved the study 
protocols. 
 
CHARGE Consortium  
 
The Aging Gene-Environment Susceptibility-Reykjavik Study (AGES) cohort originally comprised a random sample 
of 30,795 men and women born in 1907–1935 and living in Reykjavik in 1967.1 A total of 19,381 individuals attended, 
resulting in 71% recruitment rate. The study sample was divided into six groups by birth year and birth date within month. 
One group was designated for longitudinal follow-up and was examined in all stages. One group was designated a control 
group and was not included in examinations until 1991. Other groups were invited to participate in specific stages of the 
study. Between 2002 and 2006, the AGES-Reykjavik study re-examined 5764 survivors of the original cohort who had 
participated before in the Reykjavik Study. The AGES Reykjavik Study GWAS was approved by the National Bioethics 
Committee (00-063-V8+1) and the Data Protection Authority.  
 
The Atherosclerosis Risk in Communities Study (ARIC) is a multi-center prospective investigation of atherosclerotic 
disease in a predominantly bi-racial population. 2 Men and women aged 45-64 years at baseline were recruited from 4 
communities:  Forsyth County, North Carolina; Jackson, Mississippi; suburban areas of Minneapolis, Minnesota; and 
Washington County, Maryland.  A total of 15,792 individuals participated in the baseline examination in 1987-1989, with 
follow-up examinations in approximate 3-year intervals, during 1990-1992, 1993-1995, and 1996-1998.  ARIC Study 
samples were genotyped using the Affymetrix Genome-Wide Human SNP Array 6.0 (Santa Clara, California).  
 
The Austrian Stroke Prevention Study (ASPS) study is a single center prospective follow-up study on the effects of 
vascular risk factors on brain structure and function in the normal elderly population of the city of Graz, Austria. The 
procedure of recruitment and diagnostic work-up of study participants has been described previously.3,4 A total of 2007 
participants were randomly selected from the official community register stratified by gender and 5 year age groups. 
Individuals were excluded from the study if they had a history of neuropsychiatric disease, including previous stroke, 
transient ischemic attacks, and dementia, or an abnormal neurologic examination determined on the basis of a structured 
clinical interview and a physical and neurologic examination. During 2 study periods between September 1991 and March 
1994 and between January 1999 and December 2003 an extended diagnostic work-up including MRI and 
neuropsychological testing was done in 1076 individuals aged 45 to 85 years randomly selected from the entire cohort: 
509 from the first period and 567 from the second. In 1992, blood was drawn from all study participants for DNA 
extraction. They were all European Caucasians.  
The Austrian Stroke Prevention Family Study (ASPS-Fam) is a prospective single-center, community-based study on 
the cerebral effects of vascular risk factors in the normal elderly population of the city of Graz, Austria.5,6 The ASPS-Fam 
represents an extension of ASPS, which was established in 1991.3,4 Between 2006 and 2013, study participants of the 
ASPS and their first grade relatives were invited to enter ASPS-Fam. Inclusion criteria were no history of previous stroke 
or dementia and a normal neurologic examination. A total of 381 individuals from 169 families were included into the 
study. The number of members per family ranged from two to six. The entire cohort underwent an extended diagnostic 
work- up including clinical history, blood tests, cognitive testing, and a thorough vascular risk factor assessment. The 
study protocol was approved by the ethics committee of the Medical University of Graz, Austria, and written informed 
consent was obtained from all subjects. 
Carotid Atherosclerosis Progression Study (CAPS) is a community-based study from Germany. Details of the study 
have been published before. 7 In brief, members of a German primary health care service population (n=32708) were 
invited to participate. Within a predefined time limit 6962 (21.3%) agreed to participate. Of these, 5,056 were invited to 
follow-up examination after three years and 3383 (67%) participated. 1,000 individuals in whom carotid IMT 
measurements were performed, and in whom there was sufficient DNA for investigation, were genotyped and data on 
these individuals contributed to this study. Informed written consent was obtained from all participants, and the study 
protocol was approved by the local ethical committee.  
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The Cardiovascular Health Study (CHS) is a population-based cohort study of risk factors for CHD and stroke in adults 
≥65 years conducted across four field centers in the United States.8 The original predominantly Caucasian cohort of 5201 
persons was recruited in 1989-1990 from a random sample of people on Medicare eligibility lists and an additional 687 
African-Americans were enrolled subsequently for a total sample of 5888. DNA was extracted from blood samples drawn 
on all participants who consented to genetic testing at their baseline examination in 1989-90. In 2007-2008, genotyping 
was performed at the General Clinical Research Center's Phenotyping/Genotyping Laboratory at Cedars-Sinai using the 
Illumina 370CNV Duo® BeadChip system on the 3980 CHS participants who were free of CVD at baseline.  
 
Diabetes Heart Study (DHS) is a family-based observational cohort study of cardiovascular disease from a single 
research center in the United States. 9 The original predominantly (85%) European-ancestry cohort of 1443 persons was 
recruited in 1997-2005 from families with at least two type 2 diabetes affected siblings and, if possible, a non-diabetic 
sibling. Blood samples were drawn from all participants at their baseline examination and DNA was subsequently 
extracted from available samples.  
 
The Erasmus Rucphen Family Study (ERF) is comprised of a family-based cohort embedded in the Genetic Research 
in Isolated Populations (GRIP) program in the southwest of the Netherlands. 10 The aim of this program is to identify 
genetic risk factors for the development of complex disorders. In ERF, twenty-two families that had a minimum of five 
children baptized in the community church between 1850 and 1900 were identified with the help of detailed genealogical 
records. All living descendants of these couples, and their spouses, were invited to take part in the study. Comprehensive 
interviews, questionnaires, and examinations were completed at a research center in the area; approximately 3,200 
individuals participated.  The examination included the determination of carotid intima media thickness and plaque scores 
via ultrasonography.  Data collection started in June 2002 and was completed in February 2005.  
 
The Framingham Heart Study (FHS). The methods of recruitment and data collection have been described previously 
for the original Framingham Heart Study cohort  (5,209 participants ascertained systematically from two-thirds of the 
households in the town of Framingham, MA, beginning in 1948),11 the Framingham Heart Study Offspring cohort (5,124 
children of the original cohort, and spouses of those children, beginning in 197212 and the Third Generation cohort (4,095 
children of the Offspring cohort, beginning in 2002).13 The current study was conducted in 3,022 participants of the 
Offspring cohort participating in examination 6 from 1995 to 1998, who underwent contemporaneous carotid 
ultrasonography examination. Genotyping was conducted for the SNP Health Association Resource (SHARe) project 
(http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000007.v10.p5) using the Affymetrix 500K 
mapping array (250K Nsp and 250K Sty arrays) and the Affymetrix 50K supplemental gene focused array on a total of 
9,274 individuals from all three cohorts. The Framingham Heart Study was approved by the institutional review boards of 
Boston University and the National Institutes of Health.  All participants provided written informed consent. 
 
The Three-City Study (3C) is a prospective population-based cohort study conducted in three French cities, Bordeaux, 
Dijon, Montpellier, comprising 9,294 participants in total. 14 To be eligible participants had to live in the city, be 
registered on the electoral rolls in 1999, 65 years or older, and not institutionalized. The study protocol was approved by 
the Ethical Committee of the University Hospital of Kremlin-Bicêtre and each participant signed an informed consent. In 
the 3C-Dijon study 4,931 participants were recruited between March 1999 and March 2001. A carotid ultrasound 
examination was proposed to participants under the age of 85 (n=4,580), and performed with a high resolution B-mode 
system (Ultramark 9 High Definition Imaging) and a 5- to 10-MHz sounding. Owing to financial and logistic reasons, 
ultrasound examinations were not performed during the last 6 months of the baseline phase. In total 3,323 participants 
with ultrasound measures are available in 3C-Dijon. Using a standardized protocol both the left and right common carotid 
arteries, bifurcations and the internal carotid arteries (first 2cm) were scanned. 15 DNA samples of 3C-Dijon participants 
were genotyped at the Centre National de Génotypage, Evry, France (www.cng.fr), using Illumina Human610 Quad 
BeadChip systems on 4077 individuals. 16 After exclusion of individuals > 80 years, with a history of surgical procedure 
on the carotid artery, and without genome-wide genotypes, 2,518 participants had measurements of common carotid 
artery intima-media thickness and 2,473 participants had measurement of carotid plaque.  
 
The Lothian Birth Cohort 1936 (LBC1936) is a longitudinal study of ageing, derived from the Scottish Mental Survey 
of 1947, where nearly all 11 year-old children in Scotland were given a test of general cognitive ability 17-19. Survivors 
living in the Lothian area of Scotland were recruited in late-life at mean age 70 (n=1,091). Follow-up has taken place at 
ages 70, 73, 76, and 79 years. Collected data include genetic information, longitudinal epigenetic information, 
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longitudinal brain imaging, and numerous blood biomarkers, anthropomorphic and lifestyle measures. CCA intima–media 
thickness (IMT) was measured manually with calipers 20. This measures minimum, maximum and mean IMT over a 1 cm 
long segment of the common carotid artery and carotid bulb using the average of three measurements. The means of the 
maximum values were used with right and left measurements combined. carotid flow velocities, maximum stenosis 
affecting the internal carotid artery/bulb/CCA Plaques were defined by carotid stenosis of 25% or greater. Full 
measurement details are presented in Wardlaw et al. 201421. Ethics permission for the study was obtained from the Multi-
Centre Research Ethics Committee for Scotland (MREC/01/0/56) and from Lothian Research Ethics Committee 
(LBC1936: LREC/2003/2/29). The research was carried out in compliance with the Helsinki Declaration. All subjects 
gave written, informed consent. 
 
MESA (Multi-Ethnic Study of Atherosclerosis) is a study of the characteristics of subclinical cardiovascular disease 
and the risk factors that predict progression to clinically overt cardiovascular disease or progression of the subclinical 
disease. 22 MESA consisted of a diverse, population-based sample of an initial 6,814 asymptomatic men and women aged 
45-84. 38 percent of the recruited participants were white, 28 percent African American, 22 percent Hispanic, and 12 
percent Asian, predominantly of Chinese descent. Participants were recruited from six field centers across the United 
States: Wake Forest University, Columbia University, Johns Hopkins University, University of Minnesota, Northwestern 
University and University of California - Los Angeles. Participants are being followed for identification and 
characterization of cardiovascular disease events, including acute myocardial infarction and other forms of coronary heart 
disease (CHD), stroke, and congestive heart failure; for cardiovascular disease interventions; and for mortality. The first 
examination took place over two years, from July 2000 - July 2002. It was followed by four examination periods that were 
17-20 months in length. Participants have been contacted every 9 to 12 months throughout the study to assess clinical 
morbidity and mortality. 
The Netherlands Epidemiology of Obesity (NEO) study was designed for extensive phenotyping to investigate 
pathways that lead to obesity-related diseases. 23 The NEO study is a population-based, prospective cohort study that 
includes 6,671 individuals aged 45–65 years, with an oversampling of individuals with overweight or obesity. At baseline, 
information on demography, lifestyle, and medical history have been collected by questionnaires. In addition, samples of 
24-h urine, fasting and postprandial blood plasma and serum, and DNA were collected. Genotyping was performed using 
the Illumina HumanCoreExome chip, which was subsequently imputed to the 1000 genome reference panel. Participants 
underwent an extensive physical examination, including anthropometry, electrocardiography, spirometry, and 
measurement of the carotid artery intima-media thickness by ultrasonography. In random subsamples of participants, 
magnetic resonance imaging of abdominal fat, pulse wave velocity of the aorta, heart, and brain, magnetic resonance 
spectroscopy of the liver, indirect calorimetry, dual energy X-ray absorptiometry, or accelerometry measurements were 
performed. The collection of data started in September 2008 and completed at the end of September 2012.  Participants 
are currently being followed for the incidence of obesity-related diseases and mortality.  
 
The Netherlands Study of Depression and Anxiety (NESDA) is a multi-centre study designed to examine the long-term 
course and consequences of depressive and anxiety disorders (http://www.nesda.nl). 24 NESDA included both individuals 
with depressive and/or anxiety disorders and controls without psychiatric conditions. Inclusion criteria were age 18-65 
years and self-reported western European ancestry, exclusion criteria were not being fluent in Dutch and having a primary 
diagnosis of another psychiatric condition (psychotic disorder, obsessive compulsive disorder, bipolar disorder, or severe 
substance use disorder). For all participants DNA was isolated from the baseline blood sample. Through funding from the 
NIH GAIN program (www.fnih.gov/gain), whole genome scan analysis was conducted for 1859 NESDA (1702 depressed 
cases and 157 controls) participants. A hundred subjects were excluded because of various quality control issues. 25    
 
The Orkney Complex Disease Study (ORCADES) is an ongoing family-based, cross-sectional study in the isolated 
Scottish archipelago of Orkney. 26 Genetic diversity in this population is decreased compared to Mainland Scotland, 
consistent with the high levels of endogamy historically.  Fasting blood samples were collected and over 200 health-
related phenotypes and environmental exposures were measured in each individual. All participants gave informed 
consent and the study was approved by Research Ethics Committees in Orkney and Aberdeen. Genotyping was performed 
with the Illumina HumanHap300 and Illumina Omni Express beadchips.  
 
Rotterdam Study I and Rotterdam Study II (RS I and RS II). The Rotterdam Study is a prospective population-based 
cohort study to investigate the determinants of chronic diseases among participants aged 55 years and older.27 Briefly, 
residents of Ommoord, a district of Rotterdam, in the Netherlands, 55 years of age or older, were asked to participate, of 
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whom 7,983 participated (RS I). The baseline examination was conducted in 1990 - 1993 and consisted of a home 
interview and research center visit for blood samples. In 1999, inhabitants who turned 55 years of age or moved into the 
study district since the start of the study were invited of whom 3011 participated (RS II). The Medical Ethics Committee 
of Erasmus MC approved the study, and all participants gave informed consent.  
 
The Study of Health in Pomerania (SHIP) and SHIP-TREND. The Study of Health in Pomerania (SHIP) is a 
population-based study in the North-East of Germany, which consists of two independent prospectively collected cohorts 
(SHIP and SHIP-TREND)28. Their aim is assessing the prevalence and incidence of common population-based diseases 
and their risk factors. The detailed study design has been published previously. In brief, a sample from the population 
aged 20 to 79 years was drawn from population registries. First, the three cities of the region (with 17,076 to 65,977 
inhabitants) and the 12 towns (with 1,516 to 3,044 inhabitants) were selected, and then 17 out of 97 smaller towns (with 
less than 1,500 inhabitants), were drawn at random. Second, from each of the selected communities, subjects were drawn 
at random, proportional to the population size of each community and stratified by age and gender. Only individuals with 
German citizenship and main residency in the study area were included. For SHIP, baseline examinations were performed 
between 1997 and 2001. The sample finally comprised 4,308 participants. SHIP-TREND finally comprised 4420 
participants. Baseline examinations were conducted between 2008 and 2012. Individuals of both cohorts were analyzed 
separately. The carotid arteries were assessed with ultrasonography in participants at age 45 or older. Data on IMT and 
carotid plaques are available in 2,438 participants, of which 2,321 consented to take part in genome-wide association 
studies. The SHIP samples were genotyped using the Affymetrix Human SNP Array 6.0.  
 
The Cardiovascular Risk In Young Finns (YFS) study. YFS is a Finnish multi-centre study that was initiated in 1980. 
29 A total of 3596 children and adolescents aged 3-18 years participated in the first cross-sectional study. Study variables 
since childhood include serum lipids, blood pressure, obesity indices, insulin, glucose, life-style (diet, smoking, physical 
activity, alcohol), family risk and socioeconomic status. In addition, national register data on all hospitalizations with 
specific diagnoses is available from 1969 onwards. In adulthood, follow-up visits have been performed in 2001, 2007, and 
2011, with a total of 2,800 individuals from childhood having at least one follow-up in adulthood. The follow-up studies 
in 2001 and 2007 have included non-invasive ultrasound measurements of arterial function and structure, which are 
indicative of subclinical atherosclerosis. 29  DNA was extracted from blood samples drawn on all participants in 2001 and 
2007. In 2009 genotyping was performed at the Sanger institute (UK) using the custom-built Illumina BeadChip 
Human670K from 2442 YFS participants (1123 males, 1319 females) including 546677 SNPs.  
 
UCLEB (UNIVERSITY COLLEGE-LONDON SCHOOL-EDINBURGH-BRISTOL) CONSORTIUM 
 
BRHS. From 1978 to 1980, 7735 men aged 40-59 were recruited from general practices across the UK.30 A wide range of 
phenotypic measures is available for established risk markers such as lipids, blood pressure and inflammatory and 
hemostatic markers. Most of these measures were taken both at recruitment and re-examination, which occurred in 1998-
2000 when men were aged 60-79. At this re-examination 4,252 participants attended and DNA was extracted for 3945. 
Data on important behavioral variables such as cigarette and alcohol consumption, as well as physical activity, have been 
regularly collected through follow up. Well validated outcome variables including major coronary heart disease and 
stroke, as well as cause-specific mortality, continue to be collected from medical records 30 years after recruitment. 
 
The Edinburgh Artery Study (EAS) is an age-stratified random sample of men and women, aged 55-74 years, which 
was selected between August 1987 and September 1988 from the age-sex registers of ten general practices with a 
geographical and socio-economical catchment population spread throughout the city of Edinburgh, UK.30  Subjects were 
excluded if they were unfit to participate (e.g. due to severe mental illness or terminal disease); excluded individuals were 
replaced by other randomly sampled subjects. 
The Edinburgh Type 2 Diabetes Study (ET2DS) is based on an age-stratified random sample of men and women with 
type 2 diabetes, aged 60–74 years, which was selected between August 2006 and August 2007 from the Lothian Diabetes 
Register (LDR), a comprehensive database of subjects with known type 2 diabetes living in Lothian.31 Subjects were 
excluded if they did not meet WHO criteria for type 2 diabetes, or if they were physically unable to complete the clinical 
and cognitive examination. The study population is almost exclusively European. DNA was extracted at baseline. 
Physical examinations were performed by specially trained research nurses using standardised operating procedures. The 
quality of measurements was checked using observation of research staff by study investigators and inter-observer 
variability assessments were made for key variables. Blood assays were performed in accredited laboratories using 
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international standards. Retrospective data on cardiovascular disease and selected physical and biochemical variables 
were retrieved using record linkage for hospitalisations and deaths since 1985 and using data from the LDR. Subjects 
returned for further clinical examination after one year and were examined again after they had participated for 4 years. 
 
MRC1946. The Medical Research Council (MRC) National Survey of Health and Development (NSHD; also known as 
MRC 1946 birth cohort) is an on-going prospective birth cohort study consisting of a sample of all singleton births, born 
to married mothers, in England, Scotland and Wales in one week in March 1946. 32 The sample includes all births whose 
fathers were in non-manual or agricultural occupations and a randomly selected one in four of all others, whose fathers 
were in manual occupations. The original cohort comprised 2,547 women and 2,815 men who have been followed up over 
20 times since their birth. The data collected to date include cognitive function, physical, lifestyle and anthropomorphic 
measures as well as blood analytes and other measures. Through MRC Unit funding, a particularly intensive clinical 
assessment, with biological sampling, blood and urine sampling and analysis, and cardiac and vascular imaging has 
recently been completed when the cohort were aged 60-64 years.   
 
The Whitehall II (WHII) Study recruited 10,308 participants (70% men) between 1985 and 1989 from 20 London based 
civil service departments.33 In this longitudinal study blood pressure was recorded at phase 1 (1985-1988), phase 3 (1991-
1993), phase 5 (1997-1999) and phase 7 (2003-2004). DNA was stored from phase 7 from over 6,000 participants. The 
study participants are all highly phenotyped for cardiovascular and other ageing related health outcomes. 
 
IMPROVE is a multicentre, longitudinal, observational study, which involves seven recruiting centres in five European 
countries: Finland, France, Italy, the Netherlands, and Sweden.34 Each recruiting centre was incorporated separately into 
the analysis. Recruitment of a total of 3598 patients (514 per centre) was targeted. Men and women, aged from 55 to 79 
years, with at least three vascular risk factors, asymptomatic for cardiovascular diseases and free of any conditions that 
might limit longevity or IMT visualization were considered as eligible for the study. The primary objective of the 
IMPROVE study was to evaluate the association between C-IMT progression at 15 months and future vascular events 
(myocardial infarction, cardiovascular death, stroke, or any intervention in the carotid, coronary, or peripheral arterial 
districts occurring from the 15th to the 36th month of follow-up). 
 
LIFE-Adult is a population-based cohort of 10,000 adult inhabitants of the city of Leipzig, Germany. 35 Participants were 
characterized regarding life-style and environmental risk factors and clinical and subclinical signs of diseases such as 
cardiovascular diseases, type 2 diabetes or cognition. Detailed description of the cohort can be found elsewhere. 35LIFE-
Adult meets the ethical standards of the Declaration of Helsinki. The study is approved by the Ethics Committee of the 
Medical Faculty of the University Leipzig, Germany (Reg. No 263-2009-14122009). Written informed consent including 
agreement with genetic analyses was obtained from all participants.  High-resolution B-mode ultrasound images of carotid 
vessels were acquired using the GE Vivid ultrasound platform with a 12.0-MHz linear-array transducer (GE-Healthcare). 
For the assessments, subjects were in supine position.  Genotyping was performed using the Affymetrix Axiom CEU1 
SNP-array technology.  
 
LIFE-Heart is a cohort of patients with suspected or confirmed stable coronary artery disease or myocardial infarction 
collected at the Heart Center of the University of Leipzig, Germany. Study details can be found elsewhere. 36 A total of 
about 7,000 patients were recruited. LIFE-Heart meets the ethical standards of the Declaration of Helsinki. The study is 
approved by the Ethics Committee of the Medical Faculty of the University Leipzig, Germany (Reg. No 276-2005) and is 
registered at ClinicalTrials.gov (NCT00497887). Written informed consent including agreement with genetic analyses 
was obtained from all participants.  Patients with myocardial infarction were excluded from the present analysis. High-
resolution B-mode ultrasound images of carotid vessels were acquired using the GE Vivid ultrasound platform with a 
12.0-MHz linear-array transducer (GE-Healthcare). For the assessments, subjects were in supine position.  Genotyping 
was performed with either Affymetrix Axiom CEU1 or Affymetrix Axiom CADLIFE. The latter is an array containing 
Axiom CEU as genome-wide backbone and an additional custom content of about 62,500 SNPs from CAD loci.  
 
The Prospective Investigation of the Uppsala Seniors (PIVUS) cohort was randomly sampled from all men and 
women at age 70 living in Uppsala County in 2001 (n=1016; www.medsci.uu.se/PIVUS). Follow-ups were made at years 
75 (n=827) and 80 (n=606). The participants underwent a medical examination with cognitive testing (MMSE), vascular 
status assessments (endothelium-dependent vasodilation, flow-mediated dilation and pulse-wave velocity), subclinical 
atherosclerosis measurements (intima-media thickness, grey-scale median and plaque occurrence) and blood sampling 
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(low-density lipoprotein, high-density lipoprotein, triglycerides and total cholesterol) including a detailed questionnaire 
(medical history, exercise, smoking, alcohol, dietary habits and educational level). All participants were genotyped using 
the Ilumina MetaboChip genotyping array. 
 
ALSPAC The Avon Longitudinal Study of Parents and Children (ALSPAC) (http://www.alspac.bristol.ac.uk/) recruited 
14,541 pregnant women resident in Avon, UK with expected dates of delivery 1st April 1991 to 31st December 1992. 
Further details of the cohort and data collection are available in previous publications. 37,38 The study website 
(http://www.bristol.ac.uk/alspac/researchers/) contains details of all the data that is available through a fully searchable 
data dictionary. For this study data from a sub-sample of the women who were originally recruited when pregnant and 
who attended a follow-up clinic approximately 18-years after the birth of the study index child were included. All data 
collection and its use for research has been approved by the ALSPAC Ethics and Law Committee and/or UK National 
Health Service Research Ethics Committees. Participants provided informed written consent. cIMT measurements on 
these women were collected from both the left and right common carotid artery arteries, using high-resolution B 
ultrasound and scanning longitudinally 1 cm proximal to the carotid bifurcation following a standardized protocol. A 
ZONARE z.one Ultra convertible ultrasound system with L10-5 linear transducer was used. Images were focused on the 
posterior (far) wall of the artery and the zoom function was used to magnify the area. Ten-second cine loops were 
recorded in DICOM format and analyzed offline using Carotid Analyzer for Research (Vascular Research Tools 5, 
Medical Imaging Applications, LLC 2008). Three consecutive cardiac cycles were identified and three measures of cIMT 
were taken from end-diastolic frames and averaged. This was done for both right and left carotid arteries. Arterial 
distensibility was calculated as the difference between systolic and diastolic arterial diameter. The mean of the left- and 
right-sided readings was used in all analyses. The images were analyzed by a single trained reader. 
The Nijmegen Biomedical Study (NBS) (http://www.nijmegenbiomedischestudie.nl) is a population-based survey 
conducted by the Department for Health Evidence and the Department of Laboratory Medicine of the Radboud University 
Medical Centre, Nijmegen, The Netherlands. A cohort profile description of the NBS is available. 39 Briefly, in 2002, 
22,451 age and sex-stratified randomly selected adult inhabitants of Nijmegen, a city located in the eastern part of the 
Netherlands, received an invitation to fill out a postal questionnaire (QN) including questions about lifestyle, health status, 
and medical history, and to donate a blood sample for DNA isolation and biochemical studies. A total of 9350 (43%) 
persons filled out the QN, of which 6468 (69%) donated blood samples. A second, third and fourth questionnaire were 
sent out in 2005, 2008 and 2012, respectively. Approval to conduct the NBS was obtained from the Radboud university 
medical center Institutional Review Board. All participants gave written informed consent for participation in the NBS.  
 
The Malmo Diet and Cancer (MDC) study is set in Malmö, Sweden's third largest city.40 The background population 
consisted of all men born between 1923 and 1945 and all women born between 1923 and 1950 who were living in Malmö 
during the screening period 1991 to 1996 (n = 74,138). This population was identified through the Swedish national 
population registries. The final cohort consisted of 28,098 individuals (participation rate 40.8%). The subjects were 
recruited through advertisements in local media and through invitation by mail. The only exclusion criteria were 
inadequate Swedish language skills and mental incapacity. The Ethics Committee at Lund University approved the design 
of the MDC study (LU 51–90). Written informed consent was obtained from the participants. 
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Supplementary Figures 
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Supplementary Figure 1. QQ plots for meta-analyses of cIMT (A) and plaque (B) and Manhattan plots for 
cIMT (C) and plaque (D). Novel loci highlighted in red. 
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Supplementary Figure 2. Regional plots for significant loci for cIMT (A-K) and carotid plaque (L-P). Note the 
most significant SNP may not have LD with other SNPs.  
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Supplementary Figure 3. Forest plots of SNPs significantly associated with cIMT or plaque 
cIMT 
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Chr19:	11189298 (INDEL) 
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Supplementary Figure 4. Regional plot surrounding the PINX1 locus for cIMT. The top panel shows the P 
values for SNPs association with cIMT. The middle panel shows the overlaps of SNPs with annotations 
included in the combined model in fGWAS. The bottom panel shows the fitted empirical prior probability based 
on the fGWAS combined model. The SNP association shown in purple (chr8:10659406; P = 6.4 x 10-11) falls 
within active transcription (REMC.coreHMM.FAT_ADIP_DR_MSC.5_TxWk) in Adipose Derived 
Mesenchymal Stem Cells and a DNaseI-hypersensitive site (ENCODE.DHS_Maurano.CMK.DS12393) leading 
the model to assign a higher probability compared to the index SNP (index SNP chr8:10606223:INDEL; P = 
1.3 x 10-12). 
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Supplementary Figure 5. Pairwise colocalization of GWAS SNPs and tissue eQTLs. 
Colocalization results for cIMT (A) and AOR (B) and MAM (C) eQTLs 
CCDC71L 
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Colocalization of cIMT (A), Aorta eQTL (B)  
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Colocalization of plaque (A), Aorta eQTL (B), and MAM eQTL (C) 
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Supplementary Figure 6. Pairwise colocalization results for genes identified for cIMT and plaque GWAS 
meta-analysis with GWAS of coronary heart disease from CARDIOGRAMplusC4D and stroke subtypes from 
METASTROKE consortium.  Posterior probability of colocalization is shown with red being a probability of 
colocalization of the same SNP and blue the high probability of no colocalization of the same SNP with clinical 
outcomes of coronary heart disease and stroke, or subtypes. Tissue expression in AOR (aortic root), MAM 
(mammary artery); stroke subtypes are IS (ischaemic stroke), CE (cardio-embolic stroke), LVD (large vessel 
disease), SVD (small vessel disease) as defined in Methods.  
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Supplementary Figure 7. Expression of KIAA1462 gene in MAM, and plaque and CHD GWAS.  Each dot 
represents effect size estimates from associations of gene expression of KIAA1462 in MAM (x-axis) against 
associations of plaque (blue) or CHD (red) for SNPs at the KIAA1462 locus. The diamond around the dots 
represent the SNP with the strongest association across all datasets (10:30317073, rs9337951). 
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Supplementary Figure 8. GO term enrichment analysis of the protein-coding genes identified as nearest to or 
in LD with the variants for cIMT and plaque (Table 1 and Supplementary Table 5), and genes identified in 
colocalization analyses (Table 2). GO term enrichment was performed using the VLAD tool to find GO terms 
that are significantly enriched in the list of genes identified compared to the human proteome. The larger the 
size of box, the more significantly enriched the term is; the significance is represented by the p-value after the 
term name. k = number of proteins in the input list that are annotated to the term, K = number of human 
proteins in total that are annotated to the term. The lines (edges) connecting the nodes in the graph represent the 
relationships between the terms. A purple line with a solid, diamond-shaped tip represents a “part-of” 
relationship between terms; a blue line with a hollow arrow tip represents an “is-a” relationship between the 
terms. A black line with a solid arrow tip indicates that several nodes in a multi-step path are not being 
displayed in order to simplify the graphic. See VLAD tool 
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602057/). 
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Supplementary Table 1. Characteristics of the study samples 
Study Sex (F/M) Sample size cIMT Age (years) mean (SD) cIMT (mean, SD) Sample size plaque N plaques Plaque frequency 
AGES 1771/1297 3068 76.4 (5.4) 1.13 (0.16) 3053 2043 0.67 
ARIC 4596/4067 8663 54.3 (5.7) 0.76 (0.18) 8857 1626 0.18 
ASPS-FAM 176/127 303 65.5 (11.0) 0.84 (0.32)    
ASPS-FAM 439/334  65.9 (8.0)   773 490 0.63 
CAPS 443/443 886 48.9 (13.3) 0.73 (0.19)    
CHS 1265/1975 3239 72.3 (5.4) 1.03 (0.20) 3125 2069 0.66 
DHS 1 12/25 915 61.4 (9.5) 0.66 (0.12)    
ERF 1507/1214 2270 48.7 (14.4) 0.82 (0.20) 2443 1218 0.50 
FHS 1601/1403 3004 58.5 (9.7) 1.02 (0.18) 3008 530 0.18 
3C-Dijon 1581/937 2518 72.6 (4.0) 0.69 (0.11) 2473 1218 0.49 
LBC1936 363/396 759 72.8 (0.8) 0.85 (0.19) 759 220 0.29 
MESA 1309/1198 2500 62.6 (10.3) 0.87 (0.20 2492 393 0.16 
NEO 2949/2726 5675 56.0 (5.9) 1.00 (0.16)    
NESDA 368/204 572 44.7 (12.2) 0.66 (0.16) 572 86 0.15 
ORCADES 763/1128 1914 53.7 (14.9) 0.50 (0.10)    
RS I 2968/1978 4946 69.0 (8.8) 1.02 (0.21) 4910 2920 0.59 
RS II 1079/901 1980 64.7 (7.9) 0.99 (0.17) 2016 1509 0.75 
SHIP 1838/1781 3619 53.3 (13.7) 0.85 (0.20) 3666 1989 0.54 
SHIP-TREND 551/432 983 50.1 (13.7) 0.73 (0.17) 985 338 0.34 
ALSPAC 3200/0 3200 47.9 (4.5) 0.55 (0.11)    
YFS 1106 /909  2015 37.7 (5.0) 0.66 (0.10) 2013 48 0.02 
BRHS 0/889 889 78.7 (4.8) 0.79 (0.18)    
EAS 378/353 731 69.8 (5.6) 0.75 (0.18)    
ET2DS 423/445 868 68.9 (4.2) 0.94 (0.11)    
IMPROVE 1753/1636 3389 64.5 (1.9) 0.85 (0.07)    
LIFE-Adult 1677/1531 3208 59.1 (11.9) 0.76 (0.15) 4534 2726 0.60 
LIFE-Heart 684/1240 1924 62.5 (11.0) 0.78 (0.15) 2755 2117 0.77 
MDC 1093/1050 2142 57.4 (6.0)  0.73 (0.144)     
MRC1946 655/603 1258 63.3 (1.1) 0.68 (0.18)    
NBS 281/268 549 57.8 (5.2) 0.86 (0.11)    
PIVUS 482/482 964 70.2 (0.2) 0.88 (0.16)    
WHII 508/1669 2177 60.8 (5.9) 0.77 (0.19)    
36 
 
Supplementary Table 2. Study definition of carotid artery plaque 
Study Plaque definition Reference (PMID) 
AGES Of the left and right carotid bifurcation and internal carotid artery the presence of atherosclerotic lesions was be 
quantified during the ultrasound examination. The most severe lesion per segment was assessed in a semi-
quantitative manner as none, minimal, moderate and severe lesion.  17351290 
ARIC Presence of a lesion defined by abnormal arterial wall thickness, shape, or texture. Acoustic shadowing defined as 
a reduction in amplitude of echoes caused by intervening structures with high attenuation. 
9180252 
ASPS Plaque was graded according to the most severe visible changes in the CCA and ICA as 0, normal; 1,vessel wall 
thickening >1 mm; 2, minimal plaque (<2 mm); 3, moderate plaque (2 to 3 mm); 4, severe plaque (>3 mm), and 5, 
lumen completely obstructed 7800110;10408549 
CHS Largest focal lesion classified by surface characteristics, echogenicity, and texture. A discernible focal widening of 
the wall relative to adjacent segments with or without protrusion into the lumen was described according to the 
following criteria: surface—smooth, mildly irregular, markedly irregular, or ulcerated; morphology—homogeneous 
or heterogeneous; and densi- ty—hypodense, isodense, hyperdense, or calcified. 1669507 
ERF The cIMT and the carotid bifurcation were evaluated for the presence (yes/no ) of atherosclerotic lesions on both 
the near and far walls of the carotid arteries. Plaques were defined as a focal widening relative to adjacent 
segments, with protrusion into the lumen composed either of only calcified deposits or a combination of 
calcification and noncalcified material. The size or extent of the lesions was not quantified. 15845033 
FHS Defined by carotid stenosis of 25% or greater.  
LBC1936 We measured carotid flow velocities, maximum stenosis affecting the internal carotid artery/bulb/CCA Plaques 
were defined by carotid stenosis of 25% or greater. 22253310 
Life Adult & Life 
Heart 
Carotid artery plaque was defined as echogenic thickening of intimal reflection that extends into the arterial 
lumen at least 0.5 mm or 50 % of the surrounding CCA-IMT value or an intimal + medial thickness of >1.5 mm. 
Plaque presence was documented as ‘present’ or ‘absent’ for the common part and bulb of the right and left 
carotid artery, respectively. 26362881 
MESA Defined by carotid stenosis of 25% or greater. 12397006 
NESDA Widening of the intimal and medial layers relative to adjacent segments, with the area of focal increased thickness 
≥ 1.10 mm 
18763692;19065144 
21745125 
RS-I Plaques were defined as a focal widening relative to adjacent segments, with protrusion into the lumen composed 
either of only calcified deposits or a combination of calcification and noncalcified material. 19728115 
 
RS-II 
Plaques were defined as a focal widening relative to adjacent segments, with protrusion into the lumen composed 
either of only calcified deposits or a combination of calcification and noncalcified material. 19728115 
SHIP/SHIP-TREND Atherosclerotic plaques were defined as a focal thickening of the vessel wall with protrusion into the vessel lumen 
relative to adjacent segments or as a localized roughness with increased echogenicity. 11565448; 20167617  
3C-Dijon The presence of plaques was defined as localized echo structures encroaching into the vessel lumen for which the 
distance between the media–adventitia interface and the internal side of the lesion was >1 mm on the common 
carotid arteries, the carotid bifurcations, and the internal carotid arteries. 
14598854; 18063810 
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YFS The far and near walls of the left common carotid artery and carotid bulb area were scanned for the presence of 
atherosclerotic plaque, defined as a distinct area of the vessel wall protruding into the lumen >50% of the adjacent 
intima–media layer. 18263651 
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Supplementary Table 3. Study-specific genotyping, quality control, imputation and analysis 
    Sample quality control Imputation Association analysis     
Study 
Genotyping 
array Call rate Other exclusions software Reference panel software covariates 
λGC  
cIMT 
λGC  
plaque 
AGES 
Illumina 
370CNV 
BeadChip  < 0.97 HWE p-value < 10^-6 MaCH 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) ProbAbel age,sex 
0.984 1.173 
ARIC Affymetrix  6.0 <0.95 
HWE p-value <10^-5, 
MAF<0.01 IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) FAST 
age, sex, region, 10 
PCs 
1.017 1.028 
ASPS 
Illumina  
Human610-
Quad BeadChip < 98% 
HWE p-value 1<10^-6, 
MAF<0.01, sex 
mismatch, cryptic 
relatedness IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) plink age, sex 
1.000 1.013 
ASPS-
Fam 
Affymetrix 
Genome-Wide 
Human SNP 
Array 6.0 < 98% 
HWE p-value 5<10^-6, 
MAF<0.05, sex 
mismatch, cryptic 
relatedness IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) GWAF age, sex 
1.005 1.018 
CAPS Affymetrix  6.0 <0.90 
HWE p-value 1<10^-6, 
MAF<0.01, sex 
mismatch, cryptic 
relatedness 
SHAPEIT v2.778 
(phasing) and 
IMPUTE2 2.3.0 
(imputation) 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) plink2 
age,sex,pc1,pc2,pc
3,pc4 
1.008 1.019 
CHS 
Illumina 
370CNV 
BeadChip + 
Illumina IBC 
iSELECT <0.95 HWE p-value <10^-5 
MACH/miniMA
CH (whites) & 
IMPUTE v 2.2.2 
(African 
Americans) 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) R age, sex, clinic 
1.026 NA 
ERF 
Illumina 
318/370 K, 
Affymetrix 
250 K, and 
Illumina 6 K 95% 
HWE < 10^-6, MAF < 
0.01, snp call rate < 
98%, Mendelian errors miniMACH 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) 
R, GenABEL, 
ProbABEL 
age, sex (family 
structure) 
0.997 1.057 
FHS Affymetrix 500K  <0.95 HWE p-value <10^-6 
MaCH/mimima
c 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) 
R, GEE for 
dichotomous, 
LME for 
continuous trait 
Age at the 
examination cycle 
6, sex, and 10 PCs  
1.007 NA 
3C-Dijon 
Illumina 
Human610 
Quad ≤0.95  minimac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) ProbAbel/R 
Age_baseline, Sex, 
PC1, PC2, PC3, PC4 
1.018 1.006 
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LBC 
Illumina 610 
Quad V1 <95% 
HWE P <10-3, 
relatedness, MAF<1%, 
gender mismatch, SNP 
call rate <98% MiniMAC 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) Mach2qtl age, sex, 4 PCs 
1.025 1.001 
MESA Affymetrix  6.0 < 0.95 
HWE p-value < 10^-8; 
MAF < 0.005 IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) SNPTEST V2.4 
age, gender, site, 
and 4 PCs 
1.017 1.014 
NEO 
Illumina 
HumanCoreExo
me-24v1_A 
Beadchip <0.98 HWE P < 1e-5 IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) ProBABEL age, sex, 4 PCs 
1.009 1.03 
NESDA 
Affymetrix 6.0 
907K 0.9 
heterozygosity 
abs(PLINK F)>0.1; sex 
mismatch; unexpected 
relatedness minimac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) SNPTEST age, sex 
1.023 NA 
ORCADES 
Illumina 
HumanHap300  0.98 HWE p-value <10^-6 MaCH 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) ProbAbel age, sex, 3 PCs 
1.001 0.992 
RS I Illumina 550K  0.975 
HWE p-value <10^-6, 
MAF<0.001 MaCH/minimac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) ProbAbel  
1.013 NA 
RS II Illumina 550K  0.975 
HWE p-value <10^-6, 
MAF<0.001 MaCH/minimac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) ProbAbel  
0.996 NA 
SHIP Affymetrix 6.0 0.92 
duplicates, 
reported/genotyped 
gender mismatch IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) Quicktest age, sex 
1.012 NA 
SHIP-
TREND 
Illumina Human 
Omni 2.5 0.94 
duplicates, 
reported/genotyped 
gender mismatch IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) Quicktest age, sex 
0.99 NA 
DHS 
Affymetrix 
Genome-Wide 
Human SNP 
Array 5.0 0.95 
Excluded sample 
failures, sex 
discordance, 
unclear/unexpected 
sibling relationships 
(based on IBD) 
IMPUTE2  
Phase I 1000G Integrated 
Variant Set version 2, 
cosmopolitan (integrated) 
reference panel SOLAR 6.3.6 
age, sex, first two 
admixture PCs 
1.054 NA 
YFS 
Illumina 
Human670-
QuadCustom 0.95 
HWE p-value <10^-6, 
MAF<0.01 
SHAPEIT v1 and 
IMPUTE2 
1,000 Genomes Phase 1 
CEU haplotype set SNPTEST  
1.016 1.007 
ALSPAC 
Illumina 
human660W-
quad array 0.95 
HWE p-value <10^-6, 
MAF<0.01, gender 
mismatch ( X IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) SNPTEST V2.5 
age, 10 PCs 
1.013 NA 
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chromosome 
heterozygosity or 
extreme autosomal 
heterozygosity); 
unexpected 
relatedness (Pi hat of 
more than 0.125 which 
is expected to 
correspond to roughly 
12.5% alleles shared 
IBD); population 
stratification 
(determined by IBS). 
BRHS MetaboChip 0.95 
HWE p-value <10^-6, 
MAF<0.01, gender 
mismatch and 
relatedness MaCH/minimac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) snpStats age, sex 0.996 NA 
EAS MetaboChip 0.95 
HWE p-value <10^-6, 
MAF<0.01, gender 
mismatch and 
relatedness MaCH/minimac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) snpStats age, sex 1.012 NA 
ET2DS MetaboChip 0.95 
HWE p-value <10^-6, 
MAF<0.01, gender 
mismatch and 
relatedness MaCH/minimac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) snpStats age, sex 0.99 NA 
IMPROV
E 
Combined 
Metabochip 
and 
Immunochip 0.95 
HWE p-value <5^-7, 
MAF<0.01, gender 
mismatch and 
relatedness 
MACH1/Minim
ac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) Plink age, sex, 3 PC 1.054 NA 
LIFE-
Adult 
Affymetrix 
Axiom < 0.97 
HWE p-value <10^-6, 
MAF=0, gender 
mismatch and 
relatedness IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) SNPTEST v2.5 age, sex 1.016 1.007 
LIFE-
Heart 
Affymetrix 
Axiom < 0.97 
HWE p-value <10^-6, 
MAF=0, gender 
mismatch and 
relatedness IMPUTE2 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) SNPTEST v2.5 age, sex 1.010 1.004 
MRC194
6 MetaboChip 0.95 
HWE p-value <10^-6, 
MAF<0.01, gender 
mismatch and 
relatedness MaCH/minimac 
1,000 Genomes Phase 1 
CEU haplotype set snpStats age, sex 0.995 NA 
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MDC MetaboChip 0.95 
sex-mismatches, 
relatedness; SNP QC: 
callrate<95%; HWE p-
value <10^-6 N/A NA Plink age, sex 1.017 NA 
NBS 
Illumina 
HumanHapCNV
370-Duo 
BeadChip 0.95 
HWE p-value <10^-4, 
MAF<0.01, gender 
mismatch and 
relatedness IMPUTE2 
1000 Genomes phase1 v3 
together with Genome of 
The Netherlands (GoNL) 
release 5 snpStats age, sex 0.999 NA 
PIVUS MetaboChip 0.95 
HWE p-value <10^-6, 
MAF<0.01, gender 
mismatch and 
relatedness IMPUTE2 HapMap2 Plink age, sex 1.013 NA 
WHII MetaboChip 0.95 
HWE p-value <10^-6, 
MAF<0.01, gender 
mismatch and 
relatedness MaCH/minimac 
1,000 Genomes Phase I 
integrated release March 
2012 (v3) snpStats age, sex 0.995 NA 
 
NA, not available  
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Supplementary Table 4. Conditional analysis using GCTA for cIMT and plaque  
Trait SNP 
chr:positio
n 
RefAllel
e Freq Beta SE p n 
freq_gen
o bJ bJ_se pJ LD_r 
cIMT rs2912064 8:6488710 T 0.36 
-
0.0041 0.0007 1.58E-08 76752 0.64775 -0.0041 0.0007 4.30E-09 
0.0033
3 
cIMT rs11785239 8:8205010 T 0.65 0.0044 0.0008 4.48E-09 59522.7 0.35388 0.00441 0.0008 3.47E-08 0 
              
              
Columns are: freq_geno: frequency of the effect allele in the reference sample;        
bJ, bJ_se, pJ: effect size, standard error and p-value from a joint analysis of all the selected SNPs;      
LD_r: LD correlation between the SNP i and SNP i + 1 for the SNPs on the list.       
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Supplementary Table 5.Loci associated with cIMT and plaque GWAS at p< 10-7 among individuals of European ancestry 
SNP chr:position 
Nearest Coding Alleles Effect allele 
Beta (SE) p N Gene Effect/ frequency 
  Other   
cIMT        
rs515135 chr2:21286057 APOB T/C 0.18 -0.0487 (0.0009) 8.2 x 10-8 65,428 
rs139302128 chr2:242594226 ATG4B T/C 0.03 0.0487 (0.0091)  7.6 x 10-8 17,713 
         
Plaque        
rs4779614 chr15:33540117 TMCO5B  T/C 0.35 0.0869 (0.0171) 4.0 x 10-7 48,434 
rs259140 chr7:89624347 STEAP2-AS1 T/G 0.30 0.0889 (0.0177) 5.1 x 10-7 47,862 
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Supplementary Table 6. Nearest gene from top GWAS SNP of cIMT and plaque, and best colocalizing gene intersecting a region of 200kb from the listed SNP 
using STARNET tissue eQTL. Main association are SNPs with p-value < 5x10-8 (Table 1); Suggestive association are p<10-7 (Table S5). Best colocalizing gene is the 
gene with the largest posterior probability of colocalization in the joint GWAS and eQTL analysis. ngenes is the max number of genes considered across the 
tissues in  a region of +/-200kb around the GWAS SNP. 
SNP chr:position Nearest Coding Genes 
Max number 
of genes 
across tissues 
considerd in 
region (+/- 
200Kb from 
GWAS SNP) 
Max number of genes 
across tissues 
suggestive of 
association (PP3 + PP4 ³ 
50%) with both GWAS 
and STARNET eQTLs in 
region (+/- 200Kb from 
GWAS SNP) 
Best co-localizing gene (eQTL 
STARNET data, PP4) 
cIMT      
Main      
rs13225723 chr7:106416467 PIK3CG, CCDC71L, PRKAR2B 20 6 CCDC71L (AOR, PP4=97.48) 
rs148147734 chr8: 123401537 ZHX2 10 4 HAS2 (AOR, PP4=53.58) 
rs6907215 chr6:143608968  AIG1 18 7 ENSG00000217648 (MAM, PP4=47.77) 
rs7412 chr19: 45412079 APOE 61 28 APOE (SF, PP4=24.84) 
rs2912063 chr8: 6486033 MCPH1, ANGPT2 5 4 ENSG00000249898 (AOR, PP4=27.36) 
rs844396 chr16:88966667 CBFA2T3 41 23 RPL13 (AOR, PP4=10.5) 
rs200482500  chr8: 10606223 PINX1, SOX7 13 10 ENSG00000258724* (LIV, PP4=4.29) 
rs11785239 chr8:8205010 SGK223*** 8 7 PPP1R3B (VAF, PP4=3.29) 
rs201648240 chr1:208953176:INDEL  11 4 TRAF3IP3 (MAM, PP4=3.74) 
rs11196033 chr10: 114410998 VTI1A 10 4 VTI1A (LIV, PP4=2.44) 
rs224904 chr5:81637916 ATP6AP1L, ATG10 15 10 ENSG00000248870 (MAM, PP4=0.81) 
Suggestive       
rs515135 chr2:21286057 APOB 18 7 HS1BP3 (MAM, PP4=5.27) 
rs139302128 chr2:242594226 ATG4B 29 0 ENSG00000237940 (Blood, PP4=2.26) 
Plaque      
Main      
rs113309773 16:75432686 CFDP1- TMEM170A 19 10 BCAR1 (AOR, PP4=26) 
rs11413744 4:148395284:INDEL EDNRA 9 3 EDNRA (AOR, PP4=49) 
rs17477177 7:106411858 PIK3CG 21 6 CCDC71L (AOR, PP4=97) 
rs200495339 19:11189298:INDEL LDLR 69 21 ELOF1 (MAM, PP4=5.5) 
rs9632884 9:22072301 9p21 6 6 CDKN2B (AOR, PP4=39) 
Suggestive      
rs259140 7:89624347 STEAP2-AS1 7 6 CLDN12 (LIV, PP4=13) 
45 
 
rs4779614 15:33540117 TMCO5B 15 6 GREM1 (SKLM, PP4=21) 
      
*ENSG00000258724 is a long transcript that has exons derived from both PINX1 and SOX7, the encoded protein is 440 aa long, with approx. 310 aa derived 
from SOX7 exons (SOX7 is 388aa) and 130 aa derived from PINX1 exons. UniProt has included ENSG00000258724 within the SOX7, describing it as an 
alternative spliced product Q9BT81-2. Although it has aa sequence from both genes.  
** LDLR has an eQTL only in LIV, with p-value 1.73e-05. However, there is no evidence of colocalization with GWAS 
(PP4=0.5%)  
 ***SGK223, SCEL not covered in STARNET    
 
  
46 
 
Supplementary Table 7. Colocalization results between tissue-specific eQTLs of five genes (CCDC71L, PRKAR2B, ADAMTS9, LOXL4) with CHD and stroke (coloc) 
Gene.name 
eQTL 
Tissue 
GWA
S EnsemblID Chr nsnps PP0 PP1 PP2 PP3 PP4 best.snp 
best.s
np.PP
A minpi 
min
pi.s
np  
CCDC71L AOR LAS ENSG00000253276 7 3931 4.09E-33 0.6083077 6.49E-34 0.0936406 0.2980517 rs17477177 0.3 
2.37e-37, 
0.000362 
rs12705390, 
rs17398575 
ADAMTS9 AOR AS ENSG00000163638 3 4429 1.77E-19 0.5537663 5.27E-20 0.1624148 0.2838189 rs17676309 0.28 
2.06e-25, 
1.11e-05 
rs17676309, 
rs28546794 
ADAMTS9-AS1 AOR AS ENSG00000241158 3 4425 6.11E-09 0.5570923 1.82E-09 0.1630788 0.2798289 rs17676309 0.28 
4.03e-15, 
1.11e-05 
rs17676309, 
rs28546794 
CCDC71L MAM LAS ENSG00000253276 7 3931 9.88E-29 0.6494351 1.57E-29 0.1006545 0.2499103 rs17477177 0.25 
1.17e-33, 
0.000362 
rs12705390, 
rs17398575 
ADAMTS9 MAM AS ENSG00000163638 3 4429 5.59E-18 0.5899652 1.67E-18 0.1736918 0.236343 rs17676309 0.24 
7.48e-24, 
1.11e-05 
rs6775974, 
rs28546794 
PRKAR2B MAM LAS ENSG00000005249 7 3700 0.0051266 0.6869715 0.000743 0.0974628 0.2096962 rs17477177 0.21 
2.33e-08, 
0.000362 
rs12705390, 
rs17398575 
PRKAR2B AOR LAS ENSG00000005249 7 3700 0.0560082 0.6410902 0.008117 0.0908712 0.2039134 rs17398575 0.2 
6.12e-07, 
0.000362 
rs12705390, 
rs17398575 
ADAMTS9 AOR IS ENSG00000163638 3 4427 2.24E-19 0.7021656 3.70E-20 0.1142535 0.1835809 rs17676309 0.18 
2.06e-25, 
4.22e-05 
rs17676309, 
rs28546794 
LOXL4 AOR CHD* ENSG00000138131 10 3947 0.0017861 0.6938245 0.0003181 0.1217589 0.1823123 10:100011077 0.18 
5.12e-08, 
0.000135 
10:99937526, 
10:100011077 
ADAMTS9-AS1 AOR IS ENSG00000241158 3 4423 7.75E-09 0.7074084 1.28E-09 0.1147409 0.1778507 rs17676309 0.18 
4.03e-15, 
4.22e-05 
rs17676309, 
rs28546794 
ADAMTS9-AS1 MAM AS ENSG00000241158 3 4425 3.72E-12 0.650694 1.11E-12 0.1921761 0.1571299 rs9864077 0.16 
4.89e-18, 
1.11e-05 
rs9864077, 
rs28546794 
ADAMTS9 MAM IS ENSG00000163638 3 4427 6.97E-18 0.7356172 1.15E-18 0.1201778 0.1442049 rs17676309 0.14 
7.48e-24, 
4.22e-05 
rs6775974, 
rs28546794 
ADAMTS9 MAM LAS ENSG00000163638 3 4431 6.93E-18 0.731091 1.81E-18 0.1904056 0.0785035 rs6775974 0.079 
7.48e-24 
,0.00055 
rs6775974, 
rs13100017 
ADAMTS9-AS1 AOR LAS ENSG00000241158 3 4427 8.11E-09 0.7395491 2.04E-09 0.185462 0.0749889 rs17676309 0.075 
4.03e-15, 
0.00055 
rs17676309, 
rs13100017 
LOXL4 AOR SVD ENSG00000138131 10 3594 0.0018786 0.723893 0.0005205 0.1998399 0.073868 rs55917128 0.074 
5.12e-08, 
0.000772 
rs9420722, 
rs12259756 
ADAMTS9 AOR LAS ENSG00000163638 3 4431 2.35E-19 0.7367045 6.14E-20 0.1919451 0.0713503 rs17676309 0.071 
2.06e-25, 
0.00055 
rs17676309, 
rs13100017 
CCDC71L AOR AS ENSG00000253276 7 3901 5.86E-33 0.8725838 4.50E-34 0.0663521 0.0610641 rs12705390 0.061 
2.37e-37, 
0.000689 
rs12705390, 
rs35301188 
ADAMTS9-AS1 MAM CE ENSG00000241158 3 4429 4.65E-12 0.8146953 7.29E-13 0.1270808 0.0582239 rs4422297 0.058 
4.89e-18, 
0.000286 
rs9864077, 
rs9877097 
ADAMTS9 SF AS ENSG00000163638 3 4429 0.0295677 0.6977513 0.0088235 0.2076584 0.0561991 rs9870322 0.056 
2.42e-07, 
1.11e-05 
rs34401181, 
rs28546794 
PRKAR2B AOR IS ENSG00000005249 7 3674 0.0706117 0.8079406 0.0055607 0.0630979 0.0527891 rs35301188 0.053 
6.12e-07, 
0.000171 
rs12705390, 
rs35301188 
47 
 
CCDC71L MAM AS ENSG00000253276 7 3901 1.34E-28 0.8821144 1.03E-29 0.0671871 0.0506984 rs12705390 0.051 
1.17e-33, 
0.000689 
rs12705390, 
rs35301188 
PRKAR2B MAM AS ENSG00000005249 7 3671 0.0066066 0.8852717 0.0004932 0.065665 0.0419635 rs12705390 0.042 
2.33e-08, 
0.000689 
rs12705390, 
rs35301188 
PRKAR2B AOR AS ENSG00000005249 7 3671 0.0718607 0.8222194 0.0053643 0.0609821 0.0395734 rs12705390 0.04 
6.12e-07, 
0.000689 
rs12705390, 
rs35301188 
PRKAR2B MAM IS ENSG00000005249 7 3674 0.0066113 0.8858951 0.0005206 0.0693889 0.037584 rs35301188 0.038 
2.33e-08, 
0.000171 
rs12705390, 
rs35301188 
ADAMTS9-AS1 MAM LAS ENSG00000241158 3 4427 4.39E-12 0.769341 1.11E-12 0.1933401 0.037319 rs4422297 0.037 
4.89e-18, 
0.00055 
rs9864077, 
rs13100017 
CCDC71L MAM IS ENSG00000253276 7 3903 1.37E-28 0.8992305 1.10E-29 0.0718085 0.028961 rs17477177 0.029 
1.17e-33, 
0.000171 
rs12705390, 
rs35301188 
CCDC71L AOR IS ENSG00000253276 7 3903 6.04E-33 0.8994437 4.84E-34 0.0718279 0.0287284 rs17477177 0.029 
2.37e-37 
,0.000171 
rs12705390, 
rs35301188 
ADAMTS9-AS1 MAM IS ENSG00000241158 3 4423 4.77E-12 0.8349092 7.85E-13 0.137242 0.0278489 rs9864077 0.028 
4.89e-18, 
4.22e-05 
rs9864077, 
rs28546794 
ADAMTS9 SF CE ENSG00000163638 3 4433 0.0343551 0.8109885 0.0053826 0.1268386 0.0224351 rs34401181 0.022 
2.42e-07, 
0.000286 
rs34401181, 
rs9877097 
ADAMTS9 AOR CE ENSG00000163638 3 4433 2.70E-19 0.8482908 4.24E-20 0.1327174 0.0189918 rs17676309 0.019 
2.06e-25, 
0.000286 
rs17676309, 
rs9877097 
ADAMTS9-AS1 AOR CE ENSG00000241158 3 4429 9.30E-09 0.8486527 1.46E-09 0.1327987 0.0185486 rs17676309 0.019 
4.03e-15, 
0.000286 
rs17676309, 
rs9877097 
ADAMTS9 MAM CE ENSG00000163638 3 4433 8.04E-18 0.8489426 1.26E-18 0.1328271 0.0182303 rs6775974 0.018 
7.48e-24, 
0.000286 
rs6775974, 
rs9877097 
LOXL4 AOR CHD* ENSG00000138131 10 3926 0.0020307 0.7885835 0.0004917 0.190749 0.0181451 10:100011077 0.018 
5.12e-08, 
8.21e-05 
10:99937526, 
10:99772190 
ADAMTS9 SF LAS ENSG00000163638 3 4431 0.031671 0.7474688 0.0082824 0.1953009 0.017277 rs4132228 0.017 
2.42e-07, 
0.00055 
rs34401181, 
rs13100017 
ADAMTS9 SF IS ENSG00000163638 3 4427 0.0344977 0.8142271 0.0057035 0.1345058 0.0110659 rs9870322 0.011 
2.42e-07, 
4.22e-05 
rs34401181, 
rs28546794 
LOXL4 AOR AS ENSG00000138131 10 3598 0.0024461 0.9425837 0.0001273 0.0489988 0.0058441 rs10736126 0.0058 
5.12e-08 
,0.0011 
rs9420722, 
rs56354111 
LOXL4 AOR IS ENSG00000138131 10 3596 0.0024292 0.9360798 0.0001448 0.0557523 0.0055939 rs10736126 0.0056 
5.12e-08, 
0.00127 
rs9420722, 
rs56354111 
PRKAR2B SF CHD* ENSG00000005249 7 4045 0.1723597 0.051909 0.5922012 0.1782989 0.0052312 7:107288677 0.0052 
0.00283, 
6.26e-06 
7:106055635, 
7:107259721 
CCDC71L SKLM CHD* ENSG00000253276 7 4300 0.1716173 0.052503 0.5905052 0.1806061 0.0047684 7:107288677 0.0048 
0.00608, 
6.26e-06 
7:106261335, 
7:107259721 
PRKAR2B Blood CHD* ENSG00000005249 7 4045 0.1697648 0.0546227 0.5832856 0.187628 0.0046988 7:107259721 0.0047 
0.0023, 
6.26e-06 
7:106662841, 
7:107259721 
LOXL4 SF CHD* ENSG00000138131 10 3926 0.0606038 0.741122 0.0146733 0.1793971 0.0042038 10:99157571 0.0042 
4.4e-06, 
8.21e-05 
10:99157571, 
10:99772190 
ADAMTS9-AS1 SF SVD ENSG00000241158 3 4427 7.24E-05 0.8415134 1.33E-05 0.1543336 0.0040673 rs7615657 0.0041 
2e-10, 
0.000397 
rs7615657,  
rs986150 
CCDC71L Blood CHD* ENSG00000253276 7 4300 0.1639061 0.0603829 0.5639724 0.2077268 0.0040118 7:107288677 0.004 
0.00261, 
6.26e-06 
7:105473360, 
7:107259721 
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LOXL4 SKLM IS ENSG00000138131 10 3596 3.07E-16 0.9400628 1.83E-17 0.0560064 0.0039308 rs61875312 0.0039 
3.65e-22, 
0.00127 
rs61875312, 
rs56354111 
ADAMTS9-AS1 SF LAS ENSG00000241158 3 4427 6.85E-05 0.7958062 1.72E-05 0.2003393 0.0037689 rs4688481 0.0038 
2e-10, 
0.00055 
rs7615657, 
rs13100017 
PRKAR2B SKLM CHD* ENSG00000005249 7 4045 0.1684291 0.0562494 0.5786964 0.1932301 0.003395 7:107288677 0.0034 
0.000115, 
6.26e-06 
7:105773504, 
7:107259721 
LOXL4 SF SVD ENSG00000138131 10 3594 0.0635762 0.7168992 0.0176159 0.1986077 0.003301 rs7916665 0.0033 
7.06e-06, 
0.000772 
rs7916665, 
rs12259756 
CCDC71L AOR SVD ENSG00000253276 7 3899 5.67E-33 0.843492 1.03E-33 0.1534484 0.0030597 rs17477177 0.0031 
2.37e-37 
,0.000762 
rs12705390, 
rs80330319 
CCDC71L MAM SVD ENSG00000253276 7 3899 1.28E-28 0.8437459 2.34E-29 0.1534976 0.0027566 rs17477177 0.0028 
1.17e-33, 
0.000762 
rs12705390, 
rs80330319 
ADAMTS9-AS1 AOR SVD ENSG00000241158 3 4427 9.24E-09 0.8427145 1.69E-09 0.1545674 0.0027181 rs17676309 0.0027 
4.03e-15, 
0.000397 
rs17676309, 
rs986150 
ADAMTS9 AOR SVD ENSG00000163638 3 4431 2.69E-19 0.8423024 4.95E-20 0.1549963 0.0027013 rs17676309 0.0027 
2.06e-25, 
0.000397 
rs17676309, 
rs986150 
PRKAR2B AOR SVD ENSG00000005249 7 3674 0.0668727 0.7651459 0.0132921 0.1520602 0.002629 rs17398575 0.0026 
6.12e-07, 
0.000762 
rs12705390, 
rs80330319 
PRKAR2B MAM SVD ENSG00000005249 7 3674 0.006164 0.8259307 0.0012252 0.1641432 0.0025369 rs17477177 0.0025 
2.33e-08 
,0.000762 
rs12705390, 
rs80330319 
PRKAR2B SKLM CE ENSG00000005249 7 3692 0.65146 0.1965387 0.1148449 0.0346222 0.0025342 rs77209493 0.0025 
0.000522,
0.00151 
rs2395858, 
rs77209493 
LOXL4 MAM CHD* ENSG00000138131 10 3947 0.6224648 0.2242596 0.1108717 0.0399196 0.0024843 10:100011077 0.0025 
0.00114 
,0.000135 
10:99640651, 
10:100011077 
ADAMTS9 MAM SVD ENSG00000163638 3 4431 7.98E-18 0.8425552 1.47E-18 0.1550458 0.002399 rs6775974 0.0024 
7.48e-24, 
0.000397 
rs6775974,  
rs986150 
ADAMTS9 SF CHD* ENSG00000163638 3 4882 0.0334786 0.8895513 0.0027142 0.0720973 0.0021586 3:64703665 0.0022 
2.42e-07, 
0.00141 
3:64722297, 
3:63959704 
ADAMTS9 SF CHD* ENSG00000163638 3 4875 0.0278502 0.7397041 0.0083595 0.2220097 0.0020764 3:64727086 0.0021 
2.42e-07, 
3.46e-05 
3:64722297, 
3:64795689 
CCDC71L AOR CE ENSG00000253276 7 3921 5.59E-33 0.8322336 1.11E-33 0.165749 0.0020174 rs12705390 0.002 
2.37e-37, 
0.000873 
rs12705390, 
rs2528897 
PRKAR2B MAM CHD* ENSG00000005249 7 4025 0.0062249 0.8385566 0.0011291 0.1520809 0.0020086 7:106414069 0.002 
2.33e-08, 
0.00195 
7:106410777, 
7:106069830 
LOXL4 MAM SVD ENSG00000138131 10 3594 0.5889979 0.1924848 0.1632014 0.0533143 0.0020016 rs7090035 0.002 
0.00114, 
0.000772 
rs10786376, 
rs12259756 
CCDC71L MAM CHD* ENSG00000253276 7 4282 1.24E-28 0.8356551 2.40E-29 0.1624126 0.0019323 7:106414069 0.0019 
1.17e-33, 
0.00195 
7:106410777, 
7:106069830 
PRKAR2B AOR CHD* ENSG00000005249 7 4025 0.0674579 0.7773889 0.0122358 0.1409868 0.0019306 7:106416467 0.0019 
6.12e-07, 
0.00195 
7:106410777, 
7:106069830 
ADAMTS9-AS1 SF CE ENSG00000241158 3 4429 7.42E-05 0.8628251 1.16E-05 0.135186 0.001903 rs7615657 0.0019 
2e-10, 
0.000286 
rs7615657, 
rs9877097 
LOXL4 SF LAS ENSG00000138131 10 3600 0.0740788 0.8353937 0.0072211 0.0814143 0.0018921 rs11812223 0.0019 
7.06e-06, 
0.00333 
rs7916665, 
rs72835944 
LOXL4 SKLM AS ENSG00000138131 10 3598 3.10E-16 0.9487956 1.61E-17 0.0493621 0.0018423 rs61875312 0.0018 
3.65e-22, 
0.0011 
rs61875312, 
rs56354111 
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CCDC71L MAM CE ENSG00000253276 7 3921 1.27E-28 0.8324035 2.52E-29 0.1657849 0.0018115 rs12705390 0.0018 
1.17e-33, 
0.000873 
rs12705390, 
rs2528897 
PRKAR2B MAM CE ENSG00000005249 7 3692 0.0062859 0.842323 0.0011081 0.1484737 0.0018092 rs12705390 0.0018 
2.33e-08, 
0.00151 
rs12705390, 
rs77209493 
LOXL4 SKLM CE ENSG00000138131 10 3603 2.99E-16 0.9175074 2.64E-17 0.0807406 0.001752 rs7080971 0.0018 
3.65e-22, 
0.00316 
rs61875312, 
rs74931036 
CCDC71L AOR CHD* ENSG00000253276 7 4282 5.43E-33 0.8358106 1.06E-33 0.1624447 0.0017446 7:106411858 0.0017 
2.37e-37, 
0.00195 
7:106410777, 
7:106069830 
PRKAR2B AOR CE ENSG00000005249 7 3692 0.0681989 0.7805091 0.0120227 0.1375778 0.0016915 rs12705390 0.0017 
6.12e-07, 
0.00151 
rs12705390, 
rs77209493 
LOXL4 MAM CHD* ENSG00000138131 10 3926 0.5919298 0.2118275 0.143317 0.0512708 0.001655 10:99772190 0.0017 
0.00114, 
8.21e-05 
10:99640651, 
10:99772190 
LOXL4 SKLM CHD* ENSG00000138131 10 3947 2.34E-16 0.8474482 4.17E-17 0.1509288 0.001623 10:100025361 0.0016 
3.65e-22, 
0.000135 
10:100029202, 
10:100011077 
PRKAR2B LIV SVD ENSG00000005249 7 3674 0.4317674 0.4011799 0.0858215 0.0797267 0.0015045 rs17341680 0.0015 
2.48e-05, 
0.000762 
rs74620117, 
rs80330319 
LOXL4 SKLM CHD* ENSG00000138131 10 3926 2.23E-16 0.8039205 5.39E-17 0.1946293 0.0014502 10:100029202 0.0015 
3.65e-22, 
8.21e-05 
10:100029202, 
10:99772190 
ADAMTS9 SKLM CHD* ENSG00000163638 3 4875 0.461198 0.3068513 0.1384338 0.0920906 0.0014264 3:64795689 0.0014 
0.000232, 
3.46e-05 
3:63713539, 
3:64795689 
LOXL4 SKLM LAS ENSG00000138131 10 3600 2.97E-16 0.909898 2.90E-17 0.0886816 0.0014204 rs61875312 0.0014 
3.65e-22, 
0.00333 
rs61875312, 
rs72835944 
PRKAR2B LIV LAS ENSG00000005249 7 3700 0.4513608 0.420841 0.0654137 0.0609765 0.0014079 rs17398575 0.0014 
2.48e-05, 
0.000362 
rs74620117, 
rs17398575 
CCDC71L Blood CE ENSG00000253276 7 3921 0.6234356 0.2093112 0.1241796 0.0416779 0.0013957 rs10808149 0.0014 
0.00261, 
0.000873 
rs4292623, 
rs2528897 
PRKAR2B SKLM SVD ENSG00000005249 7 3674 0.6405946 0.1924532 0.1273297 0.0382397 0.0013828 rs80330319 0.0014 
0.000522, 
0.000762 
rs2395858, 
rs80330319 
ADAMTS9 SF SVD ENSG00000163638 3 4431 0.034285 0.8091349 0.0063101 0.1489052 0.0013648 rs34401181 0.0014 
2.42e-07, 
0.000397 
rs34401181, 
rs986150 
ADAMTS9 SKLM SVD ENSG00000163638 3 4431 0.5266893 0.3167343 0.0969356 0.0582804 0.0013604 rs62253780 0.0014 
0.000232,
0.000397 
rs62253780, 
rs986150 
ADAMTS9 SKLM AS ENSG00000163638 3 4429 0.480399 0.2887603 0.1433589 0.0861576 0.0013242 rs28546794 0.0013 
0.000232,
1.11e-05 
rs62253780, 
rs28546794 
ADAMTS9-AS1 MAM SVD ENSG00000241158 3 4427 4.82E-12 0.8438966 8.84E-13 0.1547984 0.001305 rs9864077 0.0013 
4.89e-18, 
0.000397 
rs9864077,  
rs986150 
LOXL4 SKLM SVD ENSG00000138131 10 3594 2.55E-16 0.7820246 7.07E-17 0.2166729 0.0013025 rs61875312 0.0013 
3.65e-22, 
0.000772 
rs61875312, 
rs12259756 
CCDC71L SF SVD ENSG00000253276 7 3899 0.1804727 0.6645391 0.0328382 0.1209048 0.0012451 rs41813 0.0012 
1.47e-06, 
0.000762 
rs41813,  
rs80330319 
ADAMTS9 SKLM LAS ENSG00000163638 3 4431 0.4944236 0.2973037 0.1292987 0.0777367 0.0012373 rs7647017 0.0012 
0.000232,
0.00055 
rs62253780, 
rs13100017 
LOXL4 AOR LAS ENSG00000138131 10 3600 0.0023557 0.9077308 0.0002296 0.0884725 0.0012114 rs9420722 0.0012 
5.12e-08, 
0.00333 
rs9420722, 
rs72835944 
CCDC71L SF LAS ENSG00000253276 7 3931 0.1839558 0.6779442 0.0292188 0.1076698 0.0012113 rs41813 0.0012 
1.47e-06, 
0.000362 
rs41813,  
rs17398575 
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LOXL4 LIV SVD ENSG00000138131 10 3594 0.5999137 0.1821957 0.166226 0.0504714 0.0011931 rs11189284 0.0012 
0.00421, 
0.000772 
rs4919231, 
rs12259756 
PRKAR2B LIV CE ENSG00000005249 7 3692 0.4396072 0.4095267 0.0774977 0.072183 0.0011854 rs192523939 0.0012 
2.48e-05, 
0.00151 
rs74620117, 
rs77209493 
LOXL4 SF CHD* ENSG00000138131 10 3947 0.0640691 0.7837829 0.0114118 0.1395937 0.0011425 10:99157571 0.0011 
4.4e-06, 
0.000135 
10:99157571, 
10:100011077 
CCDC71L SF CHD* ENSG00000253276 7 4282 0.1640672 0.6722436 0.0318909 0.1306571 0.0011412 7:106241491 0.0011 
1.47e-06, 
0.00195 
7:106241491, 
7:106069830 
ADAMTS9 LIV LAS ENSG00000163638 3 4431 0.5705171 0.2212894 0.1491983 0.0578589 0.0011363 rs9828000 0.0011 
0.00303, 
0.00055 
rs148242831, 
rs13100017 
CCDC71L SF CE ENSG00000253276 7 3921 0.1778192 0.6551427 0.0354191 0.1304838 0.0011352 rs41813 0.0011 
1.47e-06, 
0.000873 
rs41813, 
rs2528897 
ADAMTS9 LIV AS ENSG00000163638 3 4429 0.554423 0.2149017 0.1654489 0.0641191 0.0011073 rs28546794 0.0011 
0.00303, 
1.11e-05 
rs148242831, 
rs28546794 
ADAMTS9 MAM CHD* ENSG00000163638 3 4875 7.01E-18 0.7683078 2.10E-18 0.2306054 0.0010868 3:64724632 0.0011 
7.48e-24, 
3.46e-05 
3:64724632, 
3:64795689 
CCDC71L Blood CHD* ENSG00000253276 7 4282 0.6120562 0.224303 0.1189695 0.0435885 0.0010828 7:106677103 0.0011 
0.00261, 
0.00195 
7:105473360, 
7:106069830 
CCDC71L LIV SVD ENSG00000253276 7 3899 0.5969618 0.2481921 0.1086212 0.0451494 0.0010755 rs80330319 0.0011 
0.000477,
0.000762 
rs7796052, 
rs80330319 
CCDC71L SKLM CHD* ENSG00000253276 7 4282 0.6410078 0.1953698 0.124597 0.0379648 0.0010606 7:106905000 0.0011 
0.00608, 
0.00195 
7:106261335, 
7:106069830 
CCDC71L LIV CE ENSG00000253276 7 3921 0.5874642 0.2455687 0.1170146 0.0489033 0.0010492 rs2528897 0.001 
0.000477,
0.000873 
rs7796052, 
rs2528897 
PRKAR2B SF SVD ENSG00000005249 7 3674 0.6541164 0.1792241 0.1300174 0.0356137 0.0010284 rs80330319 0.001 
0.00283, 
0.000762 
rs2539830, 
rs80330319 
CCDC71L SF AS ENSG00000253276 7 3901 0.1981547 0.7296396 0.0152065 0.0559829 0.0010162 rs41813 0.001 
1.47e-06, 
0.000689 
rs41813,  
rs35301188 
PRKAR2B Blood CHD* ENSG00000005249 7 4025 0.6404674 0.2051595 0.1161707 0.0372027 0.0009997 7:106905000 0.001 
0.0023, 
0.00195 
7:106662841, 
7:106069830 
PRKAR2B SKLM CHD* ENSG00000005249 7 4025 0.6347151 0.2109128 0.1151273 0.0382463 0.0009985 7:105773504 0.001 
0.000115,
0.00195 
7:105773504, 
7:106069830 
PRKAR2B Blood SVD ENSG00000005249 7 3674 0.6465578 0.1868269 0.128515 0.0371255 0.0009748 rs80330319 
0.0009
7 
0.00327, 
0.000762 
rs1100418, 
rs80330319 
LOXL4 SF CE ENSG00000138131 10 3603 0.074789 0.8434283 0.0065829 0.074228 0.0009717 rs7916665 
0.0009
7 
7.06e-06, 
0.00316 
rs7916665, 
rs74931036 
CCDC71L SKLM CE ENSG00000253276 7 3921 0.6513005 0.1818296 0.1297299 0.0362086 0.0009314 rs2528897 
0.0009
3 
0.00608, 
0.000873 
rs62484471, 
rs2528897 
PRKAR2B SF CHD* ENSG00000005249 7 4025 0.6509339 0.1947525 0.1180692 0.0353157 0.0009287 7:106170326 
0.0009
3 
0.00283, 
0.00195 
7:106055635, 
7:106069830 
CCDC71L Blood SVD ENSG00000253276 7 3899 0.6336395 0.2116382 0.1152949 0.0384997 0.0009276 rs80330319 
0.0009
3 
0.00261, 
0.000762 
rs4292623, 
rs80330319 
ADAMTS9 LIV SVD ENSG00000163638 3 4431 0.6080313 0.2357625 0.1119064 0.0433822 0.0009176 rs3889648 
0.0009
2 
0.00303, 
0.000397 
rs148242831, 
rs986150 
CCDC71L Blood LAS ENSG00000253276 7 3931 0.6451444 0.2170113 0.1024721 0.0344601 0.0009121 rs17398575 
0.0009
1 
0.00261, 
0.000362 
rs4292623, 
rs17398575 
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CCDC71L LIV LAS ENSG00000253276 7 3931 0.6076957 0.2544617 0.0965239 0.0404086 0.0009101 rs17398575 
0.0009
1 
0.000477,
0.000362 
rs7796052, 
rs17398575 
LOXL4 AOR CE ENSG00000138131 10 3603 0.0023768 0.9159032 0.0002092 0.0806079 0.0009029 rs9420722 
9.00E-
04 
5.12e-08, 
0.00316 
rs9420722, 
rs74931036 
CCDC71L SF CHD* ENSG00000253276 7 4300 0.0441238 0.1808604 0.1518223 0.6223003 0.0008931 7:107288677 
0.0008
9 
1.47e-06, 
6.26e-06 
7:106241491, 
7:107259721 
PRKAR2B SF CE ENSG00000005249 7 3692 0.6660148 0.183367 0.1174107 0.0323166 0.000891 rs78323145 
0.0008
9 
0.00283, 
0.00151 
rs2539830, 
rs77209493 
PRKAR2B LIV IS ENSG00000005249 7 3674 0.4800416 0.4461568 0.0378036 0.0351264 0.0008717 rs35301188 
0.0008
7 
2.48e-05, 
0.000171 
rs74620117, 
rs35301188 
CCDC71L SKLM SVD ENSG00000253276 7 3899 0.6617363 0.1835966 0.1204073 0.033398 0.0008619 rs80330319 
0.0008
6 
0.00608, 
0.000762 
rs62484471, 
rs80330319 
PRKAR2B Blood CE ENSG00000005249 7 3692 0.6578288 0.1915861 0.1159676 0.0337659 0.0008516 rs112527862 
0.0008
5 
0.00327, 
0.00151 
rs1100418, 
rs77209493 
ADAMTS9 SKLM CE ENSG00000163638 3 4433 0.5392467 0.3245743 0.0844873 0.0508447 0.000847 rs9877097 
0.0008
5 
0.000232,
0.000286 
rs62253780, 
rs9877097 
ADAMTS9 LIV CE ENSG00000163638 3 4433 0.6223039 0.2415214 0.0975005 0.0378323 0.0008419 rs9877097 
0.0008
4 
0.00303, 
0.000286 
rs148242831, 
rs9877097 
ADAMTS9-AS1 AOR CHD* ENSG00000241158 3 4871 8.18E-09 0.7674213 2.47E-09 0.2317387 0.0008401 3:64730121 
0.0008
4 
4.03e-15, 
3.46e-05 
3:64730121, 
3:64795689 
ADAMTS9 SKLM IS ENSG00000163638 3 4427 0.5356097 0.3218188 0.0885525 0.0531982 0.0008208 rs28546794 
0.0008
2 
0.000232,
4.22e-05 
rs62253780, 
rs28546794 
CCDC71L SF IS ENSG00000253276 7 3903 0.1975521 0.7274867 0.0158393 0.0583201 0.0008018 rs41813 
8.00E-
04 
1.47e-06, 
0.000171 
rs41813, 
rs35301188 
ADAMTS9 AOR CHD* ENSG00000163638 3 4875 2.40E-19 0.7685322 7.20E-20 0.2306757 0.0007921 3:64730121 
0.0007
9 
2.06e-25, 
3.46e-05 
3:64730121, 
3:64795689 
ADAMTS9 LIV IS ENSG00000163638 3 4427 0.6179309 0.2395304 0.1021628 0.0395938 0.0007821 rs28546794 
0.0007
8 
0.00303, 
4.22e-05 
rs148242831, 
rs28546794 
PRKAR2B SKLM LAS ENSG00000005249 7 3700 0.670072 0.2026921 0.0971106 0.0293677 0.0007576 rs17398575 
0.0007
6 
0.000522,
0.000362 
rs2395858, 
rs17398575 
PRKAR2B SF LAS ENSG00000005249 7 3700 0.684042 0.1887365 0.0991352 0.0273453 0.0007411 rs17398575 
0.0007
4 
0.00283, 
0.000362 
rs2539830, 
rs17398575 
PRKAR2B LIV AS ENSG00000005249 7 3671 0.4819913 0.4478685 0.0359801 0.0334256 0.0007345 rs35301188 
0.0007
3 
2.48e-05, 
0.000689 
rs74620117, 
rs35301188 
ADAMTS9 MAM CHD* ENSG00000163638 3 4882 8.42E-18 0.9243395 6.82E-19 0.074932 0.0007285 3:64724632 
0.0007
3 
7.48e-24, 
0.00141 
3:64724632, 
3:63959704 
ADAMTS9-AS1 SF CHD* ENSG00000241158 3 4871 5.77E-05 0.7674573 1.74E-05 0.2317508 0.0007169 3:64546459 
0.0007
2 
2e-10, 
3.46e-05 
3:64546459, 
3:64795689 
PRKAR2B AOR CHD* ENSG00000005249 7 4045 0.0179832 0.2072933 0.0617873 0.7122205 0.0007157 7:106410777 
0.0007
2 
6.12e-07, 
6.26e-06 
7:106410777, 
7:107259721 
ADAMTS9-AS1 AOR CHD* ENSG00000241158 3 4880 9.84E-09 0.9243828 7.97E-10 0.0749099 0.0007073 3:64730121 
0.0007
1 
4.03e-15, 
0.00141 
3:64730121, 
3:63959704 
CCDC71L SKLM LAS ENSG00000253276 7 3931 0.6737573 0.1885838 0.1070169 0.0299469 0.0006951 rs17477177 
7.00E-
04 
0.00608, 
0.000362 
rs62484471, 
rs17398575 
PRKAR2B Blood LAS ENSG00000005249 7 3700 0.675512 0.1973071 0.0978989 0.0285879 0.0006941 rs17398575 
0.0006
9 
0.00327, 
0.000362 
rs1100418, 
rs17398575 
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ADAMTS9 AOR CHD* ENSG00000163638 3 4882 2.88E-19 0.9243851 2.33E-20 0.0749362 0.0006788 3:64730121 
0.0006
8 
2.06e-25, 
0.00141 
3:64730121, 
3:63959704 
ADAMTS9-AS1 MAM CHD* ENSG00000241158 3 4871 4.32E-12 0.7675453 1.30E-12 0.2317777 0.000677 3:64704860 
0.0006
8 
4.89e-18, 
3.46e-05 
3:64704891, 
3:64795689 
LOXL4 MAM LAS ENSG00000138131 10 3600 0.6860516 0.2245585 0.0668756 0.0218834 0.000631 rs147720392 
0.0006
3 
0.00114, 
0.00333 
rs10786376, 
rs72835944 
LOXL4 MAM CE ENSG00000138131 10 3603 0.691851 0.2266772 0.0608961 0.0199456 0.0006301 rs10883109 
0.0006
3 
0.00114, 
0.00316 
rs10786376, 
rs74931036 
ADAMTS9-AS1 MAM CHD* ENSG00000241158 3 4880 5.20E-12 0.9244587 4.21E-13 0.0749169 0.0006244 3:64704860 
0.0006
2 
4.89e-18, 
0.00141 
3:64704891, 
3:63959704 
PRKAR2B SKLM IS ENSG00000005249 7 3674 0.7124635 0.2139892 0.0561069 0.0168458 0.0005946 rs35301188 
0.0005
9 
0.000522,
0.000171 
rs2395858, 
rs35301188 
LOXL4 MAM IS ENSG00000138131 10 3596 0.7107836 0.2324166 0.0423763 0.0138507 0.0005729 rs56354111 
0.0005
7 
0.00114, 
0.00127 
rs10786376, 
rs56354111 
LOXL4 LIV LAS ENSG00000138131 10 3600 0.6979973 0.2126672 0.06804 0.0207249 0.0005707 rs12261952 
0.0005
7 
0.00421, 
0.00333 
rs4919231, 
rs72835944 
PRKAR2B SKLM AS ENSG00000005249 7 3671 0.7153516 0.2146708 0.0534002 0.0160194 0.000558 rs342267 
0.0005
6 
0.000522,
0.000689 
rs2395858, 
rs35301188 
LOXL4 SF IS ENSG00000138131 10 3596 0.0768314 0.8663849 0.0045806 0.0516475 0.0005556 rs11812223 
0.0005
6 
7.06e-06, 
0.00127 
rs7916665, 
rs56354111 
LOXL4 LIV CE ENSG00000138131 10 3603 0.7039359 0.2146946 0.0619598 0.018892 0.0005177 rs74931036 
0.0005
2 
0.00421, 
0.00316 
rs4919231, 
rs74931036 
LOXL4 SF AS ENSG00000138131 10 3598 0.0773849 0.8726632 0.0040275 0.0454131 0.0005112 rs11812223 
0.0005
1 
7.06e-06, 
0.0011 
rs7916665, 
rs56354111 
CCDC71L LIV IS ENSG00000253276 7 3903 0.6534674 0.2718494 0.0523934 0.0217912 0.0004985 rs35301188 
5.00E-
04 
0.000477,
0.000171 
rs7796052, 
rs35301188 
ADAMTS9-AS1 SF CHD* ENSG00000241158 3 4880 6.94E-05 0.9245099 5.63E-06 0.0749223 0.0004927 3:64546459 
0.0004
9 
2e-10, 
0.00141 
3:64546459, 
3:63959704 
CCDC71L Blood AS ENSG00000253276 7 3901 0.6957769 0.2325011 0.0533944 0.0178374 0.0004901 rs10276513 
0.0004
9 
0.00261, 
0.000689 
rs4292623, 
rs35301188 
CCDC71L Blood IS ENSG00000253276 7 3903 0.6934976 0.2318289 0.055603 0.0185826 0.0004879 rs35301188 
0.0004
9 
0.00261, 
0.000171 
rs4292623, 
rs35301188 
CCDC71L LIV AS ENSG00000253276 7 3901 0.655697 0.2725869 0.0503187 0.0209137 0.0004838 rs35301188 
0.0004
8 
0.000477,
0.000689 
rs7796052, 
rs35301188 
PRKAR2B MAM CHD* ENSG00000005249 7 4045 0.0016601 0.2236695 0.0057039 0.7684889 0.0004776 7:106410777 
0.0004
8 
2.33e-08, 
6.26e-06 
7:106410777, 
7:107259721 
ADAMTS9 SKLM CHD* ENSG00000163638 3 4882 0.5550284 0.3695635 0.044998 0.0299572 0.0004528 3:63959704 
0.0004
5 
0.000232,
0.00141 
3:63713539, 
3:63959704 
ADAMTS9-AS1 SF IS ENSG00000241158 3 4423 7.38E-05 0.8581241 1.22E-05 0.1413397 0.0004502 rs7615657 
0.0004
5 
2e-10, 
4.22e-05 
rs7615657, 
rs28546794 
PRKAR2B SF IS ENSG00000005249 7 3674 0.727297 0.1993071 0.0572751 0.0156913 0.0004296 rs35301188 
0.0004
3 
0.00283,0
.000171 
rs2539830, 
rs35301188 
LOXL4 MAM AS ENSG00000138131 10 3598 0.7159103 0.2342162 0.0372599 0.0121856 0.0004279 rs56354111 
0.0004
3 
0.00114, 
0.0011 
rs10786376, 
rs56354111 
ADAMTS9-AS1 SF AS ENSG00000241158 3 4425 6.63E-05 0.77018 1.97E-05 0.2293209 0.0004131 rs7615657 
0.0004
1 
2e-10, 
1.11e-05 
rs7615657, 
rs28546794, 
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CCDC71L SKLM AS ENSG00000253276 7 3901 0.7266208 0.2017375 0.0557614 0.0154775 0.0004029 rs77004591 
4.00E-
04 
0.00608, 
0.000689 
rs62484471 
rs35301188 
PRKAR2B Blood IS ENSG00000005249 7 3674 0.7189017 0.2077292 0.0566139 0.0163548 0.0004004 rs35301188 
4.00E-
04 
0.00327, 
0.000171 
rs1100418, 
rs35301188 
CCDC71L AOR CHD* ENSG00000253276 7 4300 1.46E-33 0.2250948 5.03E-33 0.7745081 0.0003971 7:106410777 
4.00E-
04 
2.37e-37, 
6.26e-06 
7:106410777, 
7:107259721 
PRKAR2B Blood AS ENSG00000005249 7 3671 0.7218112 0.2083625 0.0538824 0.0155501 0.0003938 rs35301188 
0.0003
9 
0.00327, 
0.000689 
rs1100418, 
rs35301188 
CCDC71L SKLM IS ENSG00000253276 7 3903 0.7242249 0.2011881 0.0580666 0.0161268 0.0003936 rs35301188 
0.0003
9 
0.00608, 
0.000171 
rs62484471, 
rs35301188 
PRKAR2B SF AS ENSG00000005249 7 3671 0.7302168 0.1999654 0.0545099 0.0149234 0.0003845 rs35301188 
0.0003
8 
0.00283, 
0.000689 
rs2539830, 
rs35301188 
LOXL4 LIV IS ENSG00000138131 10 3596 0.7233749 0.2200113 0.0431269 0.0131131 0.0003737 rs56354111 
0.0003
7 
0.00421, 
0.00127 
rs4919231, 
rs56354111 
CCDC71L MAM CHD* ENSG00000253276 7 4300 3.33E-29 0.2251007 1.15E-28 0.7745286 0.0003707 7:106410777 
0.0003
7 
1.17e-33, 
6.26e-06 
7:106410777, 
7:107259721 
LOXL4 LIV AS ENSG00000138131 10 3598 0.7285416 0.2216925 0.0379173 0.011535 0.0003137 rs56354111 
0.0003
1 
0.00421, 
0.0011 
rs4919231, 
rs56354111 
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Supplementary Table 8. Multiple trait colocalization of cIMT and plaque with AOR/MAM eQTLs (STARNET) and CHD (CARDIoGRAMPlusC4D), or stroke 
subtypes (MEGASTROKE) with probability of colocalization across three traits ≥ 75%. 
Gene.name Chr Start-Stop 
Data 
a Data b Data c 
N 
snps 
PPA
abc Best snp abc 
Min 
p_value 
data a 
Min 
p_value 
data b 
Min 
p_value 
data c 
Min p-value 
SNP data a 
Min p-value 
SNP data b 
Min p-value 
SNP data c 
ADAMTS9 3 
63588304-
65587494 AOR cIMT 
Stroke 
AS 4415 0.80 rs17676309 2.06E-25 1.49E-06 1.11E-05 rs17676309 rs17676309 rs28546794 
ADAMTS9 3 
63588304-
65587494 MAM cIMT 
Stroke 
AS 4415 0.77 rs17676309 7.48E-24 1.49E-06 1.11E-05 rs6775974 rs17676309 rs28546794 
ADAMTS9-AS1 3 
63561280-
65561009 AOR cIMT 
Stroke 
AS 4411 0.80 rs17676309 4.03E-15 1.49E-06 1.11E-05 rs17676309 rs17676309 rs28546794 
ADAMTS9-AS2 3 
63841395-
65833136 MAM cIMT 
Stroke 
AS 4533 0.76 rs17676309 6.41E-13 1.49E-06 1.11E-05 rs17676309 rs17676309 rs28546794 
CCDC71L 7 
105299372-
107298840 AOR Plaque 
Stroke 
LAS 3929 0.81 rs17477177 2.37E-37 3.71E-11 0.000362 rs12705390 rs17477177 rs17398575 
CCDC71L 7 
105299372-
107298840 AOR cIMT 
Stroke 
LAS 3910 0.81 rs12705390 2.37E-37 3.12E-09 0.000362 rs12705390 rs13225723 rs17398575 
CCDC71L 7 
105299372-
107298840 MAM cIMT 
Stroke 
LAS 3910 0.80 rs12705390 1.17E-33 3.12E-09 0.000362 rs12705390 rs13225723 rs17398575 
CCDC71L 7 
105299372-
107298840 MAM Plaque 
Stroke 
LAS 3929 0.79 rs17477177 1.17E-33 3.71E-11 0.000362 rs12705390 rs17477177 rs17398575 
CDH13 16 
82245780-
84245226 AOR cIMT CHD 7999 0.94 16:83045790 6.81E-71 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
CDH13 16 
82245780-
84245226 MAM cIMT CHD 7999 0.94 16:83045790 2.47E-46 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
EDNRA 4 
147434590-
149433978 AOR Plaque 
Stroke 
LAS 2955 0.8 rs17612742 3.16E-05 5.68E-08 1.05E-06 rs6841581 rs10305839 rs17612742 
ENSG00000232821.1 7 
18153930-
20152801 MAM Plaque CHD 4244 0.84 7:19049388 3.00E-14 0.00024 8.00E-11 7:19049388 7:18843808 7:19049388 
ENSG00000232821.1 7 
18153930-
20152801 MAM Plaque 
Stroke 
AS 3874 0.84 rs2107595 2.97E-14 0.00024 3.59E-11 rs2107595 rs2520343 rs2107595 
ENSG00000232821.1 7 
18153930-
20152801 MAM Plaque 
Stroke 
IS 3878 0.84 rs2107595 2.97E-14 0.00024 2.33E-11 rs2107595 rs2520343 rs2107595 
ENSG00000232821.1 7 
18153930-
20152801 MAM Plaque 
Stroke 
LAS 3894 0.84 rs2107595 2.97E-14 0.00024 1.44E-13 rs2107595 rs2520343 rs2107595 
ENSG00000260228.1 16 
82832549-
84832129 AOR cIMT CHD 8667 0.94 16:83045790 8.36E-18 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
ENSG00000260523.1 16 
82832949-
84832129 AOR cIMT CHD 8664 0.94 16:83045790 7.83E-30 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
ENSG00000260523.1 16 
82832949-
84832129 MAM cIMT CHD 8664 0.94 16:83045790 4.54E-17 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
ENSG00000260788.1 16 
82780756-
84780613 AOR cIMT CHD 8774 0.94 16:83045790 1.15E-33 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
ENSG00000260788.1 16 
82780756-
84780613 MAM cIMT CHD 8774 0.94 16:83045790 5.39E-20 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
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ENSG00000260832.1 16 
82006107-
84004822 AOR cIMT CHD 7626 0.94 16:83045790 3.95E-36 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
ENSG00000260832.1 16 
82006107-
84004822 MAM cIMT CHD 7626 0.94 16:83045790 5.54E-17 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
ENSG00000261103.1 16 
82748233-
84747503 AOR cIMT CHD 8809 0.94 16:83045790 9.70E-19 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
ENSG00000261410.1 16 
82425634-
84423396 AOR cIMT CHD 8403 0.94 16:83045790 1.62E-18 1.71E-05 2.11E-06 16:83045790 16:83045790 16:83045790 
ENSG00000261410.1 16 
82425634-
84423396 MAM cIMT CHD 8403 0.93 16:83045790 2.39E-12 1.71E-05 2.11E-06 16:83017777 16:83045790 16:83045790 
KIAA1462 10 
29325616-
31325032 MAM Plaque CHD 6180 0.83 10:30321598 3.00E-35 4.10E-06 4.40E-11 10:30317073 10:30317073 10:30323892 
KIAA1462 10 
29325616-
31325032 MAM cIMT CHD 6222 0.84 10:30323892 3.00E-35 1.29E-06 4.41E-11 10:30317073 10:30333622 10:30323892 
PRKAR2B 7 
105745093-
107743409 MAM cIMT 
Stroke 
LAS 3679 0.77 rs12705390 2.33E-08 3.12E-09 0.000362 rs12705390 rs13225723 rs17398575 
PRKAR2B 7 
105745093-
107743409 AOR Plaque 
Stroke 
LAS 3697 0.76 rs17477177 6.12E-07 3.71E-11 0.000362 rs12705390 rs17477177 rs17398575 
PRKAR2B 7 
105745093-
107743409 MAM Plaque 
Stroke 
LAS 3697 0.76 rs17477177 2.33E-08 3.71E-11 0.000362 rs12705390 rs17477177 rs17398575 
PRKAR2B 7 
105745093-
107743409 AOR cIMT 
Stroke 
LAS 3679 0.76 rs12705390 6.12E-07 3.12E-09 0.000362 rs12705390 rs13225723 rs17398575 
TWIST1 7 
18157302-
20154816 AOR Plaque CHD 4240 0.84 7:19049388 1.50E-10 0.00024 8.00E-11 7:19049388 7:18843808 7:19049388 
TWIST1 7 
18157302-
20154816 MAM Plaque CHD 4240 0.84 7:19049388 1.60E-37 0.00024 8.00E-11 7:19049388 7:18843808 7:19049388 
TWIST1 7 
18157302-
20154816 AOR Plaque 
Stroke 
AS 3870 0.84 rs2107595 1.46E-10 0.00024 3.59E-11 rs2107595 rs2520343 rs2107595 
TWIST1 7 
18157302-
20154816 MAM Plaque 
Stroke 
AS 3870 0.84 rs2107595 1.58E-37 0.00024 3.59E-11 rs2107595 rs2520343 rs2107595 
TWIST1 7 
18157302-
20154816 AOR Plaque 
Stroke 
IS 3874 0.84 rs2107595 1.46E-10 0.00024 2.33E-11 rs2107595 rs2520343 rs2107595 
TWIST1 7 
18157302-
20154816 MAM Plaque 
Stroke 
IS 3874 0.84 rs2107595 1.58E-37 0.00024 2.33E-11 rs2107595 rs2520343 rs2107595 
TWIST1 7 
18157302-
20154816 AOR Plaque 
Stroke 
LAS 3890 0.84 rs2107595 1.46E-10 0.00024 1.44E-13 rs2107595 rs2520343 rs2107595 
TWIST1 7 
18157302-
20154816 MAM Plaque 
Stroke 
LAS 3890 0.84 rs2107595 1.58E-37 0.00024 1.44E-13 rs2107595 rs2520343 rs2107595 
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Supplementary Table 9. GO Slim analysis for protein-coding genes identified in GWAS meta-analyses (Tables 1 and S5) of cIMT (A); plaque (B) and genes 
identified in colocalization of cIMT/plaque GWAS and tissue eQTLs (C; Table 2) or in colocalization of 3 traits; cIMT/plaque (trait1), eQTL in MAM/AOR 
(trait2), together with CHD/stroke (trait3) (D) 
A                     
Location 
relative to 
SNP 
Gene 
Symb
ol UniProt Acc. Set SNP Chromosome 
b
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Nearest VTI1A Q96AJ9 cIMT rs11196033 chr10: 114,410,998 1                       1 2 
Nearest 
SGK22
3 Q86YV5 cIMT rs11785239 chr8: 8,205,010 1                     1   2 
Nearest 
PIK3C
G P48736 cIMT rs13225723 chr7: 106,416,467   1 1 1   1 1 1 1   1 1 9 
Nearest ATG4B Q9Y4P1 cIMT rs139302128 Chr2: 242,594,226 1                   1     2 
LD FARP2 O94887 cIMT rs139302128 Chr2: 242,594,226 1  1 1  1      1  5 
LD ING5 Q8WYH8 cIMT rs139302128 Chr2: 242,594,226 1    1       1  3 
LD PDCD1 Q15116 cIMT rs139302128 Chr2: 242,594,226 1  1 1  1        4 
LD SEPT2 Q15019 cIMT rs139302128 Chr2: 242,594,226 1   1        1  3 
LD AGXT P21549 cIMT rs139302128 Chr2: 242,594,226 1       1    1  3 
LD ANO7 Q6IWH7 cIMT rs139302128 Chr2: 242,594,226 1       1  1    3 
LD BOK Q9UMX3 cIMT rs139302128 Chr2: 242,594,226 1   1        1  3 
LD HDLBP Q00341 cIMT rs139302128 Chr2: 242,594,226 1        1 1    3 
LD DTYMK P23919 cIMT rs139302128 Chr2: 242,594,226 1   1          2 
LD MTERF4 Q7Z6M4 cIMT rs139302128 Chr2: 242,594,226 1   1 1         3 
LD PASK Q96RG2 cIMT rs139302128 Chr2: 242,594,226 1    1       1  3 
57 
 
LD STK25 O00506 cIMT rs139302128 Chr2: 242,594,226 1   1        1  3 
LD GAL3ST2 Q9H3Q3 cIMT rs139302128 Chr2: 242,594,226 1        1     2 
LD NEU4 Q8WWR8 cIMT rs139302128 Chr2: 242,594,226 1        1     2 
LD CB054 Q08AI8 cIMT rs139302128 Chr2: 242,594,226              0 
LD CRCC2 H7BZ55 cIMT rs139302128 Chr2: 242,594,226              0 
LD CXXC11 Q14D33 cIMT rs139302128 Chr2: 242,594,226 1             1 
LD D2HGDH Q8N465 cIMT rs139302128 Chr2: 242,594,226 1             1 
LD KIF1A Q12756 cIMT rs139302128 Chr2: 242,594,226 1   1          2 
LD PPP1R7 Q15435 cIMT rs139302128 Chr2: 242,594,226 1             1 
LD SNED1 Q8TER0 cIMT rs139302128 Chr2: 242,594,226   1           1 
LD THAP4 Q8WY91 cIMT rs139302128 Chr2: 242,594,226     1         1 
LD 
HCG17771
98 Q9P1C0 cIMT rs139302128 Chr2: 242,594,226                           0 
Nearest ZHX2 Q9Y6X8 cIMT rs148147734 chr8: 123,401,537 1     1 1                 3 
Nearest SOX7 Q9BT81 cIMT rs200482500 chr8: 10,606,223 1   1 1       1  4 
Nearest PINX1 Q96BK5 cIMT rs200482500 chr8: 10,606,223 1             1 
LD  A0A0A6YYK5 cIMT rs200482500 chr8: 10,606,223              0 
LD CH074 Q6P047 cIMT rs200482500 chr8: 10,606,223                           0 
Nearest ATG10 Q9H0Y0 cIMT rs224904 chr5:8,163,7916 1          1 1  3 
Nearest ATP6AP1L Q52LC2 cIMT rs224904 chr5:8,163,7916        1      1 
LD RPS23 P62266 cIMT rs224904 chr5:8,163,7916 1    1         2 
Nearest MCPH1 Q8NEM0 cIMT rs2912063 chr8: 6,486,033 1     1 1   1             4 
Nearest ANGPT2 O15123 cIMT rs2912063 chr8: 6,486,033 1 1 1 1   1           1   6 
Nearest APOB P04114 cIMT rs515135 chr2:21,286,057 1 1  1 1 1   1 1 1 1 1 10 
LD TDRD15 B5MCY1 cIMT rs515135 chr2:21,286,057              0 
Nearest AIG1 Q9NVV5 cIMT rs6907215 chr6:143,608,968                  1         1 
Nearest APOE P02649 cIMT rs7412 chr19: 45,412,079 1 1  1 1  1 1 1 1 1 1 1 11 
LD APOC1 P02654 cIMT rs7412 chr19: 45,412,079 1       1 1 1 1  1 6 
LD NECTIN2 Q92692 cIMT rs7412 chr19: 45,412,079 1  1 1  1      1  5 
LD TOMM40 O96008 cIMT rs7412 chr19: 45,412,079 1             1           2 
Nearest CBFA2T3 O75081 cIMT rs844396 chr16:88,966,667 1     1 1 1               4 
Count of proteins per GO category    35 4 6 16 11 7 3 7 8 5 5 15 5  
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Nearest PIK3CG P48736 Plaque rs17477177 chr7:106411858 1 1 1     1 1 1 1     1 1 9 
Nearest 
TMEM170
A Q8WVE7 Plaque rs113309773 
chr16:75432686
:INDEL 1                         1 
Nearest CFDP1 Q9UEE9 Plaque rs113309773 
chr16:75432686
:INDEL 1   1 1                   3 
Nearest LDLR P01130 Plaque rs200495339 chr19:11189298 1   1 1 1 1 1 1 1 1  1 10 
LD SMARCA4 P51532 Plaque rs200495339 chr19:11189298 1     1 1             1   4 
Nearest EDNRA P25101 Plaque rs11413744 
chr4:148395284
:INDEL 1 1   1               1  4 
Nearest TMCO5B A8MYB1 Plaque rs4779614 chr15:33540117                           0 
Count of proteins per GO category    6 2 2 4 2 2 2 2 2 1 1 3 2  
 
  
59 
 
C                   
Gene Symbol 
UniProt 
Acc. Set SNP Chromosome 
b
io
lo
gi
ca
l_
p
ro
ce
ss
 
ca
rd
io
va
sc
u
la
r 
sy
st
e
m
 d
ev
e
lo
p
m
e
n
t 
ce
ll 
ad
h
e
si
o
n
 
d
e
ve
lo
p
m
e
n
ta
l p
ro
ce
ss
 
ge
n
e
 e
xp
re
ss
io
n
 
im
m
u
n
e
 s
ys
te
m
 p
ro
ce
ss
 
in
fl
am
m
at
o
ry
 r
e
sp
o
n
se
 
io
n
 t
ra
n
sp
o
rt
 
lip
id
 m
e
ta
b
o
lic
 p
ro
ce
ss
 
lip
id
 t
ra
n
sp
o
rt
 
lip
o
p
ro
te
in
 m
et
ab
o
lic
 p
ro
ce
ss
 
si
gn
al
in
g 
ve
si
cl
e
-m
e
d
ia
te
d
 t
ra
n
sp
o
rt
 
 C
o
u
n
t 
o
f 
G
O
 c
at
e
go
ri
e
s 
p
er
 p
ro
te
in
 
CCDC71L Q8N9Z2 cIMT/Plaque rs12705390 chr7:106,416,467       1         1         2 
PRKAR2B P31323 cIMT/Plaque rs12705390 chr7:105,299,372 1               1     1   3 
ADAMTS9 Q9P2N4 cIMT rs17676309  chr3:63,561,280 1 1 1 1                 1 5 
LOXL4 Q96JB6 cIMT rs55917128  chr10:99,017,729 1                       1 2 
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ADAMTS9 Q9P2N4 cIMT chr3:63,588,304 1 1 1 1         1 5 
CHD13 P55290 cIMT chr16:82,245,780 1 1 1   1             1 1 6 
KIAA1462 Q9P266 cIMT/Plaque chr10:29,325,616 1 1         1  3 
CCDC71L Q8N9Z2 cIMT/Plaque chr7:105,299,372     1         1         2 
PRKAR2B P31323 cIMT/Plaque chr7:105,745,093 1        1   1  3 
TWIST1 Q15672 Plaque chr7:18,157,302 1 1   1 1     1 1     1   7 
EDNRA P25101 Plaque chr4:147,434,590 1 1   1               1   4 
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Supplementary Table 10. Druggability of genes in loci genome-wide significantly associated with cIMT or plaque. Tier 1, 2 and 3 druggability are highlighed: 
Tier 1=approved drugs and drugs in clinical development; Tier 2= proteins closely related to drug targets or associated with drug-compounds; Tier 3: extracellular 
proteins and members of key drug-target families 
Gene.na
me 
Drug
tier drug_type 
Distance  
to gene variant trait strength chr.position 
Nearest 
coding 
gene 
Max number 
of  genes 
across 
tissues 
considered 
in region 
Max 
number of  
genes 
across 
tissues 
suggestive 
assoc 
ATG4B 2 SMALL_MOL -1 rs139302128 cIMT Suggestive chr2:242594226 ATG4B 29 0 
ALPL 2 SMALL_MOL,BIO_MOL -1 rs147771110 Plaque Suggestive chr1:21868723 ALPL 23 0 
LDLR 2 SMALL_MOL,BIO_MOL 10739 rs200495339 Plaque Main chr19:11189298 LDLR 70 22 
APOB 1 SMALL_MOL,BIO_MOL 19112 rs515135 cIMT Suggestive chr2:21286057 APOB 18 7 
EDNRA 1 SMALL_MOL,BIO_MOL -1 rs6841473 Plaque Suggestive chr4:148407652 EDNRA 9 3 
APOE 3 BIO_MOL -1 rs7412 cIMT Main chr19: 45412079 APOE 61 28 
Best coloc variant alleles chr consequence_types 
Rsq 
EUR 
ENSG00000237940 
(Blood, PP4=2.26) rs139302128 C/T 2 
non_coding_transcript_variant,non_coding_transcript_exon_variant,NMD_transcrip
t_variant,intron_variant,downstream_gene_variant 0.5 
DDOST (SF, PP4=4) rs147771110 -/C 1 non_coding_transcript_variant,intron_variant,regulatory_region_variant 0.5 
ELOF1 (MAM, PP4=5.1) rs200495339 G/- 19 intergenic_variant 0.5 
HS1BP3 (MAM, PP4=5.27) rs515135 T/C 2 intergenic_variant 0.5 
EDNRA (AOR, PP4=37.62) rs6841473 C/T 4 non_coding_transcript_variant,NMD_transcript_variant,intron_variant 0.5 
APOE (SF, PP4=24.84) rs7412 C/T 19 missense_variant,downstream_gene_variant 0.5 
 
description biotype gene 
Gene start 
pos Gene end pos 
Gene window 
overlap 
autophagy related 4B, cysteine peptidase [Source:HGNC Symbol;Acc:20790] protein_coding KNOWN 242576628 242613272 36645  
alkaline phosphatase, liver/bone/kidney [Source:HGNC Symbol;Acc:438] protein_coding KNOWN 21835858 21904905 61570  
low density lipoprotein receptor [Source:HGNC Symbol;Acc:6547] protein_coding KNOWN 11200038 11244492 10875  
apolipoprotein B [Source:HGNC Symbol;Acc:603] protein_coding KNOWN 21224301 21266945 3307  
endothelin receptor type A [Source:HGNC Symbol;Acc:3179] protein_coding KNOWN 148402069 148466106 40938  
apolipoprotein E [Source:HGNC Symbol;Acc:613] protein_coding KNOWN 45409011 45412650 572  
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Supplementary Table 11. Druggability of genes identified in colocalization analyses 
Gene Chr Position nsnps data1 PPA.abc data3 data2 Gene description 
CDH13 16 
82245780-
84245226 7999 AOR 0.94 
CARDIoGRAMplus
C4D cIMT cadherin 13 [Source:HGNC Symbol;Acc:1753] 
CDH13 16 
82245780-
84245226 7999 MAM 0.94 
CARDIoGRAMplus
C4D cIMT cadherin 13 [Source:HGNC Symbol;Acc:1753] 
ADAMTS9 3 
63588304-
65587494 4415 AOR 0.80 AS cIMT 
ADAM metallopeptidase with thrombospondin type 1 
motif, 9 [Source:HGNC Symbol;Acc:13202] 
ADAMTS9 3 
63588304-
65587494 4415 MAM 0.77 AS cIMT 
ADAM metallopeptidase with thrombospondin type 1 
motif, 9 [Source:HGNC Symbol;Acc:13202] 
EDNRA 4 
147434590-
149433978 2955 AOR 0.80 LAS PLAQUE 
endothelin receptor type A [Source:HGNC 
Symbol;Acc:3179] 
 
 
Gene Drug tier Drug type Compound activities Compound activities 
CDH13 tier 3 BIO_MOL 0 0 
CDH13 tier 3 BIO_MOL 0 0 
ADAMTS9 tier 3 BIO_MOL 0 0 
ADAMTS9 tier 3 BIO_MOL 0 0 
EDNRA tier 1 BIO_MOL | SMALL_MOL 46 1* 
 
*Drugs and indications: AMBRISENTAN (Andes disease,SCD,Asma,HT,HYPERTENSION PULM,Vasc,HPAH,UIP,PULMONARY HYPERTENSION, PRIMARY, 
DEXFENFLURAMINE-ASSOCIATED,Pulmonary Hypertension, Primary, Fenfluramine-Associated,PAH,Pph1 With Hht,Mountain Sickness,Altitude 
Hypoxia)|BOSENTAN (Asma,MOD,HYPERTENSION PULM,COLD,melanoma,PSS,Optic Nerve Ischemia,CDH,Morgagni hernia,Bochdalek hernia,HPAH,Anterior 
Ischemic Optic Neuropathy,Posterior Ischemic Optic Neuropathy,Chronic Airflow Obstruction,UIP,PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-
ASSOCIATED,Pulmonary Hypertension, Primary, Fenfluramine-Associated,PAH,Pph1 With Hht)|CLAZOSENTAN (Subarachnoid bleeding,Perinatal Subarachnoid 
Hemorrhage,Spontaneous subarachnoid hemorrhage,Aneurysmal Subarachnoid Hemorrhage,INTRACRANIAL SUBARACHNOID HEMORRHAGE)|DARUSENTAN 
(HT)|MACITENTAN (HYPERTENSION PULM,PSS,HPAH,UIP,PULMONARY HYPERTENSION, PRIMARY, DEXFENFLURAMINE-ASSOCIATED,Pulmonary Hypertension, 
Primary, Fenfluramine-Associated,PAH,Pph1 With Hht)|SPARSENTAN (FSGS,HT,Segmental hyalinosis)|TEZOSENTAN (Weak heart,CHF,HYPERTENSION 
PULM,LVF,rvf,Myocardial Failure,Heart Decompensation)|ZIBOTENTAN (Ca breast,CA,Liver,Tumor,prostate tumor,Liver Dysfunction,BENIGN TUMOR,Ca 
prostate,Human Mammary Neoplasm,Breast tumor)  
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